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Breast cancer is the second-most prevalent cancer worldwide and most commonly occurring 
cancer type in women with roughly 2 million new cases diagnosed in 2018. Current breast cancer 
management is a multidisciplinary approach which uses imaging for detection and monitoring, 
and tissue biopsy for diagnosis. Limitations within these technologies shifted focus toward liquid 
biopsies which are minimally invasive, allow for frequent sampling with a simple blood draw, 
and represent the heterogeneity of the cancer. One biomarker recently discovered for use in 
liquid biopsies are extracellular vesicles (EVs). Their ability to stably carry mRNA through 
circulation makes them a potentially suitable marker for mRNA expression profiling, a 
diagnostic method currently implemented in breast cancer management. Herein, an EV 
microfluidic affinity purification (EV-MAP) device was developed for selective isolation of 
disease-associated EVs for mRNA expression analysis. The EV-MAP assay produced a 99 ± 1% 
specificity for the gene panel used in this study through the implementation of 1% PVP-40/1% 
BSA blocking and 0.2% Tween 20® washing agents . A proteolytic digestion strategy using 
proteinase K and subsequent sonication was developed to remove EVs from the device surfaces 
and produced a release efficiency of 99 ± 1%. EV-MAP also captured two distinct populations of 
disease-associated EVs through orthogonal markers either selecting for mesenchymal or 
epithelial-derived EVs, with one population showing gene expression profiling differences from 
the cells of origin while the mesenchymal populations resulted in similar mRNA expression 
profiles to their host cells. Finally, healthy controls and breast cancer patient samples were 
processed through the EV-MAP assay. ddPCR of these samples resulted in several genes 
showing copy numbers below the limit of detection of ddPCR, thereby highlighting the mass 
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Chapter 1. Introduction 
1.1 Breast cancer – Prevalence and risk factors 
Nearly 10 million people worldwide died from cancer in 2018 [1]. Cancer is the second 
leading cause of death in the United States (Figure 1) only behind heart diseases and accounted 
for 22% of all deaths in 2017 [2]. The American Cancer Society estimates 1,762,450 new cases 
for 2019 [3]. The high occurrence and mortality rates highlight a need to improve upon 
technologies or tools for early detection, diagnosis, monitoring of treatment response, and 
detecting relapse.  
 
Only the 10 leading causes of death are included in this graph, with death rates age-adjusted. 1Statistically significant 
decrease in mortality rates from 2016 to 2017 with a p-value < 0.05. 2Statistically significant increase in mortality 
rates from 2016 to 2017 from a p-value < 0.05. Reproduced from “Mortality in the United States, 2017,” by S. L. 
Murry, J. Xu, K. D. Kochanek, and E. Arias, 2018. [2]. 
Figure 1. Death Rates in the United States from 2016 and 2017.  
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Of all cancer cases, 80-90% are carcinomas [4], originating in the epithelial tissue that 
forms the skin and lines organs and body cavities, such as the chest. Carcinomas are further 
classified based on the type of epithelial cells – squamous cell carcinomas, basal cell carcinomas, 
and adenocarcinomas. Adenocarcinomas form in glandular cells capable of secretion, which 
keeps tissues moist, and form in organs or glands capable of secretion such as the breasts [4]. 
Breast cancer is the second most common type of cancer worldwide (Figure 2A) and was 
estimated to cause 626,679 deaths in 2018 according to the International Society of Cancer 
Research (ISCR) [1]. When categorizing cancer cases and fatalities based on sex, breast cancer is 
the most common in women (Figure 2B) [1], accounting for 15% of the estimated new cancer 
cases in the United States [3]. One in eight women will develop an invasive breast cancer in their 
lifetime, which can spread from the primary tumor into the surrounding soft tissue.  
If a breast cancer is non-invasive, it is considered in situ and remains at the site of origin. 
The two main types of non-invasive or in situ breast cancers are ductal carcinoma in situ (DCIS) 
and lobular carcinoma in situ (LCIS). Yet, 80% of all breast cancer cases in the United States are 
invasive [5]. Invasive breast carcinomas can be differentiated into 21 histological subtypes [5] 
depending on the original cancer site or the architecture of the tissue and cells. Table 1 lists the 
estimated prevalence and mortality of in situ and invasive breast cancers by age for 2017 [6]. 
Other non-carcinoma breast cancer types exist as well, such as pagets disease of the nipple, 
inflammatory breast cancer, and breast sarcomas. However, these types combined account for 




Most women develop breast cancer after the age of 40, with the highest occurrence found 
in women between the ages of 50 and 70 (Table 1) [6]. Age plays an important role in the 
overall risk, along with other risk factors such as inherited conditions, past treatment with 
hormonal therapy, and a high density of breast tissue (ratio of fatty tissue to glandular tissue). 
(A) Estimated incidence rates (out of 18.1 million total cases) of cancers in both sexes separated by cancer type. (B) 
Incidence and mortality rates (out of 8.6 and 4.2 million estimated cases, respectively) for women. Reproduced with 
permission from John Wiley and Sons: “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and 
Mortality Worldwide for 36 Cancers in 185 Countries,” by F. Bray et al., 2018, CA: a cancer journal for clinicians, 
68:6, p. 400, © 2018 by the American Cancer Society [1]. 
 
Figure 2. Estimated new cases and deaths for the 10 most common cancer types worldwide from 2018. 
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For example, women with dense breast tissue are five times more likely to develop breast cancer 
than the average-risk population [8]. More than 50% of women in the United states live with 
dense breast tissue [9], making this a highly prevalent risk factor affecting not only the potential 
for developing breast cancer but also the performance of screening modalities. Furthermore, 
though most breast cancer cases diagnosed do not correlate with family history, females who 
inherit mutations in the BRCA1 or BRCA2 genes have a 60% higher risk in developing breast 
cancer compared to the general population [10]. Screening is often the first step in breast cancer 
clinical management for average-risk individuals, but high-risk patients may receive additional 
genetic counseling and risk assessment either preceding or in conjunction with routine screening. 
For example, doctors may suggest women with BRCA1 or BRCA2 mutations undergo genetic 
counseling [5] to determine whether high-risk screening modalities are beneficial over the 
screening methods routinely used for average-risk individuals.  
 
Table 1. Estimated in situ and invasive breast cancer cases and mortalities in 2017 in the United States 
  In situ cases Invasive cases Deaths 
Age No. % No. % No.  % 
< 40 1,610 3% 11,160 4% 990 2% 
40-49 12,440 20% 36,920 15% 3,480 9% 
50-59 17,680 28% 58,620 23% 7,590 19% 
60-69 17,550 28% 68,070 27% 9,420 23% 
70-79 10,370 16% 47,860 19% 8,220 20% 
80 + 3,760 6% 30,080 12% 10,910 27% 
All ages 63,410   252,710   40,610   
 
These cases are further categorized based on the 10-year age group with which they are most expected to develop. 
Percentages may not sum to 100 because estimates were rounded to the nearest ten. Reproduced with permission from 
John Wiley and Sons: “Breast Cancer Statistics, 2017, racial disparity in mortality by state,” by C. E. DeSantis et al., 
2017, CA: a cancer journal for clinicians, 67:6, p. 440. © 2017 by the American Cancer Society [6]. 
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 Figure 3 outlines the general sequence of events in the medical care of breast cancer, 
from screening to treatment and surveilling recurrence. This management pathway is a 
multidisciplinary process that involves various forms of testing to accurately detect, diagnose, 
monitor treatment, and survey for disease recurrence. It is important for each patient to 
communicate with their physician and vice versa to ensure the process flow is beneficial to each 
unique individual with the final aim of curing disease or prolonging life.  
Screening serves to detect cancer early. If an abnormality is present or symptoms arise, further analysis of the 
suspicious lesion is often performed through secondary imaging to detect false positives resulting from screening 
tools. If the imaging results show potential malignancy, official diagnosis of the disease includes a pathological 
review of the tissue to stage the disease as well as imaging in certain cases where systemic disease may be present. 
Various treatment options may be administered, with monitoring of the response to treatment occurring particularly 
in cases of non-curative disease. Patients showing complete response to primary treatment undergo surveillance to 





























Figure 3. Flow chart outlining the general breast cancer management pathway. 
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Breast cancer is detected through either a routine mammogram or a mammogram 
prescribed to a patient based on physical signs of breast cancer such as breast swelling, pain, or 
redness. Some patients may undergo diagnostic imaging to help identify any benign lesions or 
clinically occult cancer. If the abnormality is still suspected of being malignant, a tissue biopsy is 
performed and analyzed to stage the disease (pathology), assign a grade (histology), and analyze 
the molecular components (molecular analysis) to formulate a treatment plan. If the breast cancer 
spreads to other locations in the body (metastasizes), the goal of treatment is to prolong life and 
requires monitoring the patient’s response. However, upon conclusion of curative treatment, 
patients are surveilled using the same methods applied for screening.  Each of these breast cancer 
management steps will be discussed further below. 
1.2 Breast cancer clinical management 
1.2.2 Screening 
Clinically oriented organizations such as the U.S. Preventive Services Task Force (USPSTF), 
American Cancer Society (ACS), and American College of Radiology (ACR) developed 
screening guidelines to standardize early detection of breast cancer. All suggest mammography 
screening starting at the age of 50, while some recommend giving women the option to screen 
from the age of 40 to 49 for average-risk patients [11-13]. This age range is determined based on 
the higher incurred risk of developing cancer in women between 50-69 years of age, with risk 




 Mammography uses low-dose x-rays to construct images of each breast. Specialized 
equipment compresses the breast between two plates, so the low-dose x-rays can pass through 
the fatty tissue. Cysts, microcalcifications, or potential cancerous tumors are distinguishable by a 
bright appearance compared to the surrounding tissue. Figure 4 shows a comparison of these 
breast conditions when viewed from a screening mammogram. Screening mammography has an 
average clinical sensitivity of 87% and clinical specificity of 89% [14], which decreases to 
76.5% and 83.8%, respectively, for women younger than 40 [15]. Clinical sensitivity refers to 
how well the test or equipment identifies disease when disease is present, with a high sensitivity 
correlating to the majority of disease-positive cases being detected. Clinical specificity measures 
The first image (far left) shows a mammogram for healthy normal breast tissue. Breast cysts (second image from 
left) show up often as a light oval, with a secondary imaging technique often required to distinguish them from a 
cancerous mass. Calcifications (third image from left) either form on the macro- or microscale (this picture shows 
microcalcification) and are characterized by a cluster or single white dots. Breast cancer often shows up as a bright 
white dense mass in an irregular shape. Normal breast image reproduced from the Austin Diagnostic Clinic, 2019, 
retrieved from https://www.adclinic.com/confusion-breast-density/Cyst. Copyright 2019 by The Austin Diagnostic 
Clinic. Cyst image adapted from Radiopaedia, 2019, retrieved from open access https://radiopaedia.org/cases/ 
simple-breast-cyst-2. Copyright 2019 by Radiopaedia. Calicification image reproduced from Radiopaedia, 2019, 
retrieved from https://radiopaedia.org/cases/benign-breast-calcifications?lang=us. © 2019 by Radiopaedia. Breast 
cancer image adapted from http://www.klinikaikozpont.u-szeged.hu/radiology/radio/emlo/aemlo6a.htm, 2019. 
 
Normal breast Breast cyst Calcification Cancer mass 
Figure 4. Example mammograms showing various breast conditions. 
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the ability of a test to correctly distinguish individuals who do not have the disease and would 
therefore result in a low specificity if many false positive readings occurred. The median size of 
tumor detected through a screening mammogram is 1-1.5 cm [16]. Screening mammography 
often detects early stage breast cancer before a mass becomes large enough to identify through 
physical examination [17]. However, this improvement is countered by false positives. The low 
positive predictive value (PPV 28.6%)  yields  a ~70% chance of incorrectly identifying disease 
in a patient free of cancer [14], which further decreases for younger women. Because false 
positives cause unnecessary emotional strain and are followed by time-consuming and costly 
tests that may not be covered by insurance, mammograms are not recommended for screening 
average-risk individuals until 40 years of age.  
Dense breast tissue creates an additional limitation for mammography. For these patients, 
clinical sensitivity drops to 47.8-64.4%, because x-rays cannot travel through thick glandular 
tissue [18]. Such dense breast tissue also appears bright on a mammogram, making cancerous 
masses difficult to detect (Figure 5). This limitation led the ACR to recommend additional 
ultrasound imaging for patients with dense breast tissue [13]. Studies have found supplementary 
ultrasound detected more breast cancer cases than solo mammography for women with dense 
breast tissue [19-22]. However, results from these studies only show a slight improvement in 
detecting cancer over screening with mammography alone [19]. Further, imaging by both 
ultrasound and mammography increases false positive rates, potentially decreasing the PPV to 
16% [20]. Due to this inherent disadvantage, the ACS and National Comprehensive Cancer 




For women at high familial risk for developing breast cancer, in particular due to any 
BRCA1 or BRCA2 gene mutations, mammography sensitivity decreases to 33-55%, potentially 
because many of these women are suggested to screen earlier than 50 years of age [23-26]. 
Therefore, the ACS and ACR both include adjunct magnetic resonance imaging (MRI) screening 
with annual mammography for high-risk individuals [12, 13]. MRI uses magnetic fields to 
manipulate hydrogen atoms in the water of tissues, often with the aid of contrast agents, and can 
differentiate fatty, glandular, and cancer tissues. With this high contrast, MRIs achieve 
sensitivities up to 100% [24, 27-31], consistently higher than mammography, ultrasound, or both 
modalities combined for high-risk patients [24, 32-35]. However, MRI screening is not 
recommended for average-risk patients due to high cost and lower accessibility to the equipment, 
and therefore is only suggested as supplemental to mammography for high-risk patients because 
The light appearance of the dense breast tissue (far right) could hide potential cancerous masses from view, making 
mammography a less accurate method of screening for breast cancer in the dense breast patient population. Image 
reproduced from The Austin Diagnostic Clinic, 2019, retrieved from open access https://www.adclinic.com 




Scattered areas of 
density Heterogeneously dense 
Extremely 
dense 
Figure 5. Gradient of mammograms taken from breasts with mostly fatty tissue to dense breast tissue. 
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the lower specificity requires unnecessary biopsies or tests (as low as 80% in detecting benign 
growths) [23].  
1.2.3 Diagnosis 
Diagnostic imaging. If an abnormality is found during screening, or if symptoms arise, the 
NCCN recommends follow-up according to the ACR Breast Imaging Reporting and Data System 
(BI-RADS) category. The BI-RADS categories range from 1 to 5 with increased risk that the 
detected lesion is indeed malignant, and the NCCN recommends increased levels of intervention 
based on these categories (Table 2) [36]. 
Table 2. Breast Imaging Reporting and Data System (BI-RADS) categories. 
BI-RADS 
category 
Number indication Action required 
1-2 1= negative finding 
2 = benign 
Resume routine screening 
3 3 = probably benign Diagnostic mammogram after 6 months, followed by 
imaging every 6–12 months for 1–2 subsequent years. 
If the lesion increases in size or changes in 
characteristics, perform biopsy 
4-5 4 = suspicious of 
malignancy 
5 = highly 
suggestive of 
malignancy 
Perform tissue biopsy – pathology report must correlate 
with imaging findings. If they are discordant, repeat 
breast imaging with additional surgical excision 
recommended if findings still discordant 
6 6 = proven 
malignancy 
Malignancy previously proven by biopsy, patients 
undergoing treatment. Perform follow-up 
mammograms. 
 
Firstly, initial screens may produce false positives if benign lesions are mistaken for 
tumors. For results indicating that a mass is probably benign, clinicians withhold intervention 
Categories are listed with their associated imaging follow-up tests described in accordance with the NCCN guidelines. 
The radiologist assesses mammography images to provide a score, dictating what subsequent diagnostic imaging 
methods are prudent. Information adapted from “Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN 
Clinical Practice Guidelines in Oncology”, T. B. Bevers et al., 2018, 11:16 [36]. 
11 
 
until a second diagnostic mammogram 6 months later [36]. Unlike screening mammography that 
only captures two images from two viewpoints for each breast, diagnostic mammography 
incorporates additional views and can magnify the suspected area. Patients with physical 
symptoms present may receive a diagnostic mammography directly. 
Similarly, ultrasound or MRI may be combined with diagnostic mammography to further 
exclude benign masses and clinically occult cancers [37], particularly if patients are symptomatic 
despite negative screening results [36]. For example, using both diagnostic mammography and 
ultrasound in symptomatic patients resulted in a clinical specificity of 97.7%, clinical sensitivity 
of 92%, and a 68% PPV [38]. Likewise, MRI may be helpful for patients exhibiting nipple 
discharge or skin discoloration whose initial diagnostic images point toward negative results or a 
benign mass (BI-RADS category 1-3) [39]. In such cases, MRI has been useful to identify less 
common breast cancers such as pagets disease of the nipple or inflammatory breast cancer [40, 
41]. 
Staging of the Disease. The American Joint Committee on Cancer (AJCC) developed a standard 
reporting system for staging breast cancers called the TNM classification system[42]. The 
system combines results from several analyses, such as imaging and lymph node biopsies, to 
“score” the tumor size (T), lymph node status (N), and presence of metastases (M).  
The T score measures the diameter of the primary tumor through screening and 
diagnostic images. A “T0” score is reserved for an unobservable tumor. Tumors smaller than 2 
cm are scored as “T1”, between 2-5 cm as “T2”, and greater than 5 cm as “T3” (Table 3). The 
highest score “T4” indicates that the tumor has spread outside the breast to the chest wall and/or 
skin[42]. Table 3 only provides an abridged version of the T scores used in staging. 
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T0 No tumor physically 
evident 
T1 tumor is ≤ 2cm 
T2 tumor is >2cm but ≤ 5cm 
T3 tumor is > 5cm 
T4 
Tumor has spread to the 
chest wall and/or skin 
 
Beyond the breast tumor itself, clinicians gauge the metastatic spread of the cancer 
through the lymph system. The first area for breast cancer to often spread to is the sentinel lymph 
nodes found closest to the breast, with the second site for metastases most commonly in the 
axillary lymph nodes under the arm. Via a tracer dye injected into the breast, sentinel lymph 
nodes first absorbing the tracer are removed for an initial screening by histological analysis, 
which if present, are further extracted during tumor resection [43]. The number of lymph nodes 
containing cancer cells, the abundance of cancer cells in the lymph nodes, and corresponding 
imaging results are compiled into a “N” score (Table 4) that gauges the potential for metastatic 
spread. 
  
The general prognosis worsens, and stage increases from T0 to T4. Information summarized from “Breast Cancer – 
Major Changes in the American Joint Committee on Cancer eighth edition cancer staging manual,” A. E. Giuliano et 
al., 2017, 8th edition, p. 624, John Wiley and Sons. ©2017 by the American Cancer Society [42]. 
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Table 4. Abridged scoring system for nodal status from the AJCC TNM staging system. 
N score lymph node status 
N0 
1. axillary and other nearby lymph nodes do not have cancer present OR                                                         
2. only show individual cancer cells (cells ≤ 0.2mm) 
N1 
N1mi 
1. micro metastases between 0.2-2mm OR                                                                                      
2. > 200 cancer cells present 
N1a metastases in 1-3 axillary lymph nodes, with at least 1 cancer cell group > 2mm 
N1b metastases in internal mammary nodes 
N1c 
metastases in 1-3 axillary lymph nodes, with at least 1 cancer cell group > 2mm AND 
metastases in internal mammary nodes 
N2 
N2a metastases in 4-9 axillary lymph nodes, with at least 1 cancer cell group > 2mm 
N2b 
metastases in internal mammary nodes present on mammogram or other imaging, with no 
metastases found in axillary lymph nodes 
N3 
N3a 
1. ≥ 10 axillary lymph nodes show metastases, with at least 1 cancer cell group > 2mm 
OR                                                                                                                                                    
2. metastases in infraclavicular nodes 
N3b 
1. Metastases in 1-9 axillary lymph nodes with at least 1 cell group > 2mm AND 
metastases in internal mammary nodes seen on mammogram OR                                                             
2. Metastases in 4-9 axillary lymph nodes with at least 1 cancer cell group > 2mm AND 
metastases in internal mammary nodes seen from biopsy 
N3c metastases in nodes above the clavicle 
 
Cancer spread through lymph nodes is considered local metastases. In advanced stages of 
breast cancer, distant metastases can form. Clinicians traditionally examine metastases through 
computed tomography (CT) of the chest, bones, abdomen, and pelvis. The NCCN recommends 
additional imaging when symptoms and/or physical examination leads clinicians to suspect 
metastases [44]. For example, bone scans rely on an injectable radioactive tracer to highlight 
metastatic cancer cells disseminated into the bones, but the NCCN only advises such tests if the 
patient experiences bone pain [44]. Similarly, a chest CT for lung metastasis is mainly 
implemented when pulmonary symptoms are present, and abdominal CT/MRI imaging is only 
Prognosis worsens, and stage increases from a score of N0 to N3. Information summarized from “Breast Cancer – 
Major Changes in the American Joint Committee on Cancer eighth edition cancer staging manual,” A. E. Giuliano et 
al., 2017, 8th edition, p. 624, John Wiley and Sons. ©2017 by the American Cancer Society [42].  
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performed in cases of abnormal physical examination results. Regardless of where distant 
metastases are found, patients are reported with a score of “M1” indicating metastatic breast 
cancer. However, imaging is not shown to provide any clear benefit for the early detection of 
metastases in asymptomatic patients and are only ordered at the discretion of the physician [45]. 
Thus, although CT imaging is required for staging metastases, a patient can be reported as “no 
metastasis present” or “M0” in the AJCC staging system without any imaging results [46].  
The findings for tumor size, node status, and presence of metastasis are all combined in 
officially staging breast cancer according to the AJCC’s TNM system [46]. The stages range 
from 0-4, with higher stages corresponding to worse prognosis. Stage 0 refers to any breast 
cancer diagnosed as non-invasive; stage I-III describes any locally invasive breast cancer; and 
any sign of metastasis (M1) results in a stage IV diagnosis. The AJCC changed their staging 
guidelines to also require assessment of the grade of the breast cancer and receptor status in 2017 
[46], with these clinical procedures described below. 
Grading Breast Cancer by Histology. For all malignant cases, tissue biopsies of the tumor are 
required. Biopsies are extracted prior to treatment or surgery, with some patients receiving an 
additional biopsy after surgery to assess response to neoadjuvant therapy or determine the need 
for adjuvant therapies. Pathologists perform histological analyses of the extracted tumor 
material. These results coupled with image findings (discussed above) help clinicians stage the 
cancer and predict prognosis for disease progression.  
Pathologists “grade” the cancer by microscopic examination of cell morphology. This 
grade is based on the glandular formation, mitotic index, and nuclear pleomorphism observed in 
the tissue sample. Glandular formation refers to the ability of cancerous cells to form normal 
glands (tubules). Pathologists observe the number of cancer cells actively dividing (mitotic 
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index) and the shape and structure of cells, particularly gauging size of the cell nuclei and 
uniformity in cell size and shape (nuclear pleomorphism). Invasive breast cancers are graded on 
a scale from I to III, with a grade III breast cancer correlating with abnormally-shaped, fast-
growing cells that cannot form organized glandular structures (Figure 6). 
 
Molecular Profiling. Molecular analysis provides physicians with important information for 
deciding personalized treatment pathways for each breast cancer patient. The American Society 
of Clinical Oncology (ASCO) recommends testing of three markers for all invasive breast cancer 
Glands are formed by a high level of cellular organization. Nuclear pleomorphism compares the cell morphology and 
nucleus size to that found in normal breast epithelial cells, with higher differentiation correlating to a worse grade and 
prognosis. An increase in mitotic count refers to a high level of proliferation found in higher grade cases of breast 
cancer. Reproduced from open access Johns Hopkins Medicine Pathology, 2019, Retrieved from https://pathology.jh 
u.edu/breast/my -results/staging-grade/. © 2019 by Johns Hopkins University. 
Glandular/Tubular 
Differentiation: >75% of 
tumor forms glands 
Nuclear Pleomorphism: 
Uniform cells with small 
nuclei similar in size to 
normal breast epithelial cells 
Mitotic Count: <7 mitoses 
per 10 high power fields 
Glandular/Tubular 
Differentiation: 10% to 75% 
of tumor forms glands 
Nuclear Pleomorphism: 
Cells larger than normal with 
open vesicular nuclei and 
moderate variability in size 
and shape 
Mitotic Count: 8-15 mitoses 
per 10 high power fields 
Glandular/Tubular 
Differentiation: <10% of 
tumor forms glands 
Nuclear Pleomorphism: 
Cells with vesicular nuclei 
and marked variability in size 
and shape 
Mitotic Count: >16 mitoses 
per 10 high power fields 
Grade 1 Grade 2 Grade 3 
Figure 6. Illustrations outlining the characteristics associated with the 3 grades of breast cancer. 
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cases: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER2) [47]. Tumor expression of ER or PR indicates promoted tumor growth in 
response to their associated hormones (estrogen or progesterone, respectively), whereas 
overexpression of the HER2 receptor causes uncontrolled cell growth. Another less-common 
molecular marker tested is Ki-67. The Ki-67 protein is expressed during the mitotic process 
within cells and a strong indicator of cancer proliferation. Pathological reports use 
immunohistochemical staining against these molecular markers to indicate whether a tumor is 
positive or negative based on the level of proteins present in the tissue sample.In the last two 
decades, researchers have used gene expression profiling to further classify breast cancers from 
the traditional molecular analysis, with the benefit of providing separate information about 
prognostic prediction or predictive response to therapy to help make treatment decisions. Perou 
et al. first profiled 65 breast cancer tissue specimens and found most tumors had high expression 
of either basal or luminal epithelial cell genes, or overexpression of the HER2 gene [48]. Another 
group of tumors showed profiles similar to normal breast specimens in their high expression of 
basal and adipose genes but low expression of luminal genes (Figure 7A). Since this 
revolutionary study, further transcriptomic profiling [49] has resulted in defining four major 
molecular subtypes for breast cancer : luminal A, luminal B, HER2 enriched, and basal-like. 
Luminal A and B are largely differentiated based on the high expression of proliferation genes 
found in luminal B but not in luminal A.  
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(A) Prat et al. performed gene and array clustering according to the intrinsic gene list from Parker et al. [56] with the 
top dendrogram colors correlating to the intrinsic subtypes. Expression patterns to the right are based on gene clusters 
associated with breast cancer tumors or cell lines. The colored squares correlate to the transcript abundance, light red 
= high expression and light green = low expression. Reproduced from John Wiley and Sons: “Deconstructing the 
molecular portraits of breast cancer,” by A. Prat and C. M Perou, 2011, Mol. Onc., 5:1, p.7. © 2011 with permission 
under CC BY-NC-ND: https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode. Link to publication: https:/ 
/doi.ord/10.1016/j.molonc.2010.11.003 [54]. (B) Five intrinsic subtypes and their gene expression similarity to breast 
cell gene signatures. Reprinted by permission from Springer Nature: Nature Reviews, Nat. Med.  “Mammary 
development meets cancer genomics,” b C.M Perou, 2011, 15:8, p. 843, John Wiley and Sons. © 2011. 


























Gene expression signatures 
Intrinsic Breast Cancer Subtypes 
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 Herschkowitz et al. discovered another molecular subtype claudin-low, recognized by the 
low expression of claudins and genes involved in cell adhesion with relatively high expression of 
genes associated with the epithelial to mesenchymal transition (EMT) (Figure 7A) [50]. The 
epithelial-to-mesenchymal transition occurs when epithelial cells lose expression of cell adhesion 
proteins such as epithelial cell adhesion molecule, EpCAM [51], or E-cadherin [52] and gain 
expression of mesenchymal genes such as vimentin, VIM [52], or fibroblast activation protein, 
FAPα [53]. This causes epithelial cells to detach and become mobile due to the development of 
mesenchymal-like morphology [54]. Each molecular subtype correlates with a certain level of 
mesenchymal or epithelial (luminal/basal cell) phenotypic expression with claudin-low showing 
the highest signature of mesenchymal characteristics while luminal subtypes fall on the opposite 
end, mostly expressing luminal epithelial cell characteristics (Figure 7B). 
The discovery of intrinsic molecular subtypes complemented the traditional classification 
system with molecular analyses that advanced clinical methods for classifying breast cancer 
cases. Though certain types of receptor status appear more frequently in one intrinsic subtype 
over another (Figure 8) , no one combination of hormone or HER2 status definitively identifies a 
single subtype. Thus, traditional receptor testing remains as the standard method of molecular 
analysis used in clinics.  
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The subtypes have also been characterized for their correlation with various breast cancer 
grades. Claudin-low and basal-like breast cancer often result in a clinical grade of III, with 
roughly 70 and 80% showing triple negative receptor status [55]. HER2 enriched is also 
associated with a high clinical grade of III [56], while a majority of luminal A and luminal B are 
grade I-II or II-III, respectively [56]. Luminal B are higher grade than luminal A due to the 
overexpression of proliferation genes allowing cancer to grow more rapidly.Research has 
Most claudin-low and basal-like cases are triple negative or show low expression of all three common molecular 
markers. Luminal A and B often exhibit higher expression of the estrogen receptor, while HER2-enriched breast 
cancer shows high expression of HER2 in an average of 66% of cases. Reproduced from John Wiley and Sons: 
“Deconstructing the molecular portraits of breast cancer,” by A. Prat and C. M Perou, 2011, Mol. Onc., 5:1, p.7. © 
2011 with permission under CC BY-NC-ND: https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode. Link to 
publication: https:/ /doi.ord/10.1016/j.molonc.2010.11.003 [54]. 
 
Figure 8. Relative prevalence of ER+/HER2+, ER-/HER2+, ER-/HER2- in the five intrinsic molecular subtypes. 
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demonstrated the ability of these subtypes to predict disease prognosis or progression with high 
certainty. To help investigate the prognosis and progression using a simplified gene panel, Parker 
et al. [57] discovered 50 genes to best differentiate the intrinsic subtypes [57]. Total RNA 
(TRNA) was extracted from 189 formalin-fixed paraffin-embedded (FFPE) or fresh frozen 
samples for subsequent reverse transcription (RT) and quantitative PCR (qPCR) as well as 
microarray profiling. The selected genes and their respective expressions in the four main 
intrinsic subtypes and in normal control samples taken from reduction mammoplasty are shown 
in Figure 9. Prat et al. assessed a large sample set that included microarray samples tested by 
Parker et al. [57] for disease-free and overall survival rates based on each intrinsic subtype [58]. 
A separate predictor was used for the identification of claudin-low samples. HER2 enriched, 
basal, luminal B, and claudin-low all follow a similarly short disease-free timeframe and lower 
likelihood of long-term survival when compared to luminal A (Figure 10). Luminal A breast 
cancers showed a much higher chance for exceeding 5 years with no disease recurrence after 
treatment.  
 The realization that molecular profiling breast cancers through gene expression assays 
could highly predict the risk of recurrence or relapse led to the Food and Drug Administration 
(FDA) approving several assays for use in the clinic, with one analyzing the 50 genes discovered 
by Parker et al. [57] (test called Prosigna®). The Prosigna® Breast Cancer Prognostic Gene 
Signature Assay examines these genes (listed in Figure 9) through direct expression 
measurements from isolated RNA using nCounter® technology (NanoString). A reporter probe 
to supply the fluorescent signal and capture probe to immobilize the product are hybridized 
directly to the specific RNA of interest. The expression data is collected through a scanning 
fluorescence microscope, and a software program then creates a risk of relapse score that can 
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predict the distant recurrence-free survival at 10 years for post-menopausal women diagnosed 
with breast cancer who are HR+, node-negative (stage I or II) or node-positive (stage II). These 
risk scores stratify patients based on the benefit of chemotherapy post-surgery in addition to 
hormone therapy [59].  
Figure 9. Prevalent expression of PAM50 genes to four intrinsic subtypes and normal breast tissue 
Clustering of the 50 genes included in the PAM50 predictor and their associated genes of interest based on the intrinsic 
subtypes. Green correlates to highly expressed genes in the intrinsic subtype; red-colored genes are expressed at low 
levels; and black is either normal expression or blocked out. Reprinted with permission. © 2009 by American Society 
of Clinical Oncology. All rights reserved. Parker, J et al:  “Supervised risk predictor of breast cancer based on intrinsic 
subtypes,” J Clin Oncol, Vol. 27(8), supplemental figure A2. [56].  
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In contrast to the PAM50 assay, the Oncotype Dx examines only 21 genes through 
traditional reverse transcription-polymerase chain reaction (RT-PCR) that are important to cell 
proliferation or found in ER and HER2 signaling processes [60]. The expression patterns of these 
genes correlate with a quantitative score to distinguish the probability of recurrence. The 
recurrence score distinguishes hormone receptor positive (HR+) cases based on predicted 
hormone therapy outcome and sensitivity to chemotherapy [61], providing physicians with 
knowledge pertinent to choosing the right treatment pathway. 
Though molecular profiling is a promising new classification technique for breast cancer 
management, it is currently still not fully recommended in clinical guidelines and is considered 
secondary to the traditional pathology testing of receptor status for determining treatment and 
prognosis. Thus, these assays are only ordered if enough tissue sample remains after the initial 
Figure 10. Figure 10. Kaplan-Meier graph showing overall and relapse free survival for 
The UNC337 dataset of breast cancer tumor gene expressions were analyzed by Prat et al. [57]. This data was later 
modified in a publication by Prat and Perou [54]. The sample cohort included a heterogeneous spread of treatment 
methods that were determined based on molecular marker status. The graphs mainly show the markedly higher 
relapse-free and overall survival associated with the Luminal A subtype. . Reprinted from John Wiley and Sons: 
“Deconstructing the molecular portraits of breast cancer,” by A. Prat and C. M Perou, 2011, Mol. Oncol., 5:1, p.7. © 
2011 with permission under CC BY-NC-ND: https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode. Link to 





pathological review, and the AJCC does not require gene profiling as a test for assigning stage 
[46]. However, the AJCC does suggest use of the Oncotype Dx assay in certain cases because 
large-scale prospective clinical trial data supports its use in determining whether adjuvant 
chemotherapy is beneficial to patients with node-negative, ER+ breast cancer [62]. 
1.2.4 Treatment 
After receiving the pathological report, a physician will use the information to create a treatment 
plan for each patient. The one common treatment procedure for all breast cancer patients is 
surgical excision to remove the cancer tissue. However, the extent of breast removal is guided by 
the prognosis of the disease, the predicted response to therapies, and the stage at which the breast 
cancer is diagnosed. 
A surgeon may either perform a mastectomy or lumpectomy. Mastectomy requires 
removal of the entire breast and is often the optimal option for women with small breasts and 
large tumors, many malignant calcifications, locally advanced breast cancer, or patients with 
tumors fixed to the chest wall [63]. However, for patients that desire breast-conserving surgery, 
the therapies discussed below can also be administered prior to surgery (neoadjuvant therapy) to 
shrink the tumor before resection [63]. For patients with non-invasive or early stage invasive 
cancers without wide spread of the tumor, a lumpectomy is suggested that only resects cancerous 
tissue and leaves most of the breast intact. While this surgery is less invasive and cosmetically 
maintains the breast, radiation after surgery (adjuvant therapy) targets remaining cancer cells and 
yields comparable overall survival rates to mastectomies [64]. 
For all cases, pathologists perform margin assessment of the excised mass to detect any 
remaining signs of cancer. The “margin” is a ring of non-cancerous tissue surrounding the 
cancerous mass that the surgeon removes. If cancer cells are present within this margin, re-
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excision is required to remove remaining cancer from the breast. Lymph nodes removed during 
surgery are similarly tested to detect whether the cancer has further metastasized into the lymph 
system and if there is a need for additional surgical resection. 
Adjuvant therapy is recommended for patients with a strong likelihood of cancer 
recurrence [63]. However, a physician may suggest adjuvant therapy to any patient after surgery 
to kill any residual cancer cells, as they cannot be visualized through current diagnostic tools. 
Chemotherapy serves as the only systemic treatment option beneficial to patients with triple 
negative (ER-/PR-/HER2-) breast cancer [63]. For patients positive for hormone receptors, 
endocrine therapies can be implemented to inhibit cancer growth by targeting estrogen and 
progesterone receptors. The most common drugs used for ER-based endocrine therapy are 
tamoxifen or aromatase inhibitors. Tamoxifen blocks estrogen from binding to ER receptors, 
while aromatase inhibitors block the enzymes responsible for producing estrogen [65]. Both 
older and younger women either post or pre-menopause have benefited from tamoxifen, but only 
post-menopausal women over the age of 50 saw equivalent or greater benefit when compared to 
chemotherapy [66]. For patients with HER2 enriched cancers, the anti-HER2-specific 
monoclonal antibody (mAb) trastuzumab binds to HER2, which causes the receptor to 
internalize and blocks signal transduction. The addition of trastuzumab to chemotherapy 
regimens for HER2+ untreated metastatic breast cancer was found to increase overall survival 
and create a longer median response to therapy when compared to chemotherapy alone [67].  
The use of adjuvant therapy as a precautionary treatment to kill residual cancer cells in 
any patient highlights the fact that no widely available diagnostic tool is sensitive enough to 
detect minimal residual disease (MRD) at very low cancer burden, which can cause relapse if not 
treated. Thus, while the initial clinical workflow for diagnosis and the identification of therapy 
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options is robust, adjuvant therapy is often recommended because of the technological limits 
currently found in monitoring of disease. 
1.2.5 Monitoring 
Monitoring is important to gauge both treatment response and detect cancer recurrence. For all 
but metastatic cases, monitoring is considered “surveillance” and is enacted after treatment. The 
ASCO [68] and NCCN [44] recommends routine physical examinations and mammography after 
treatment, but only 40% of recurrence cases are identified by mammography before physical 
symptoms arise [69]. More sensitive testing, such as MRI, is not used for routine monitoring and 
is instead only supplemental for inconclusive mammograms [13]. Further, patients who undergo 
mastectomy having their entire breast removed currently have no guidelines to address the 
replacement of mammograms as the surveillance method. It is left to each individual health 
professional or their institution in how to monitor post-mastectomy patients [70]. 
Once breast cancer has metastasized to distal sites, the disease is considered incurable. 
Tests throughout treatment seek to assess the overall health of the patient (toxicity levels) and 
response to treatment. For example, if the disease continues to progress through treatment, 
physicians may switch therapies. The NCCN recommends a panel of tests for patient health that 
are continuously monitored throughout treatment – such as liver function tests and complete 
blood counts – and CT imaging for monitoring progression of the metastases in the pelvis, chest, 
abdomen, or bone scans for monitoring metastasis in bones [71]. However, bone scans can result 
in false positives due to the metabolic activity created by several disease processes such as 
trauma or inflammation that is visualized through the use of radio tracers [71]. CT monitors 
treatment response based on the size of the tumor, with tracers sometimes applied to increase 
contrast in the images. Both tests require 2-3 hours for the radio tracer to reach the metastatic 
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sites from the intravenous injection, expose the patient to additional radiation, and can cause 
side-effects from the contrast agents that range from nausea to cardiopulmonary arrest [72].  
Combining positron emission tomography (PET) with CT can visualize both anatomic 
changes and abnormal metabolic activity because fluorodeoxyglucose (FDG) is taken up by the 
rapidly growing cancer cells (FDG PET/CT). PET/CT is an optional method advised by the 
NCCN [70], but there are no reproducible or validated standards of assessment for the 
examination of PET/CT images for detecting disease progression. However, standardization 
could make PET/CT a powerful tool as multiple studies found PET/CT to outperform 
conventional imaging technologies in detecting metastasis [73, 74]. 
Though imaging remains the mainstay for assessing treatment response in metastatic 
breast cancer, it is still limited by sampling frequency and tumor size detection limit (7 mm for 
PET [75] and 3 mm for CT [76]). Furthermore, the interpretation of results is heavily dependent 
on the experience of the radiologist analyzing the images. These limitations among others 
motivated researchers to look for other tests to monitor disease such as liquid biopsies (discussed 
below). 
1.3 Liquid biopsy biomarkers for cancer management 
Liquid biopsies extract biomarkers from bodily fluids such as blood, urine, saliva, or 
cerebrospinal fluid for detecting, diagnosing, or monitoring disease. Liquid biopsies are 
minimally invasive and more accurately convey the heterogeneous nature of the cancer [77] as 
well as allowing for more frequent sampling over a longer period of time when compared to 
traditional tissue biopsy or imaging modalities. Therefore, clinical oncology research has focused 
on investigating the ability of liquid biopsies to provide equivalent or further information to 
clinicians than is currently received from solid tissue analysis or imaging. The impact of a liquid 
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biopsy depends highly upon the biomarker chosen for assessment. The biomarker needs to 
provide actionable information by indicating disease recurrence, progression, or survival to help 
guide treatment decisions [78]. 
1.3.1 Proteins 
In monitoring treatment response for metastatic breast cancer (MBC) patients, protein markers 
that are indicative of tumor progression can also be analyzed through a serum sample taken from 
a blood draw. The tests are minimally invasive to the patient [79] and may show signs of relapse 
prior to physical symptoms appearing on images. While ASCO does not approve such testing as 
stand-alone care for monitoring, they can facilitate certain treatment decisions, such as the 
benefit of continuing therapy, when used in conjunction with imaging [62]. One protein 
biomarker is a glycoprotein overexpressed on cancer cells, mucin 1 (MUC-1). Another protein 
marker is normally associated with fetal development that decreases in healthy adults but is 
elevated to 40-50% in metastatic breast cancer patients and is called carcinoembryonic antigen 
(CEA).  
Two common immunoassays use antibodies (Abs) that target different epitopes of the 
same solubilized MUC-1 protein, cancer antigen 15-3 (CA 15-3) and cancer antigen 27.29 (CA 
27.29). Though both markers have generated concordant results [80], CA 15-3 is backed by more 
clinical data validating its role in monitoring metastatic breast cancer [79]. CA 15-3 is associated 
with a 60.3% clinical sensitivity and 71.1% clinical specificity in determining therapy response, 
with the combined use of CEA increasing the specificity to 95.5% but decreasing the sensitivity 
to 32% [81]. Because CEA is only elevated in 40-50% of metastatic breast cancer patients, 
current clinical guidelines only suggest CEA be used in cases where CA 15-3 is inconclusive due 
to normal MUC-1 antigen levels [62]. The ASCO only suggests any tumor markers for 
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monitoring metastatic breast cancer when disease cannot be measured by imaging. For example, 
neither PET [75] or CT imaging can detect a tumor < 3 mm [76]. In these cases, an increase in 
these tumor markers coincides with treatment failure. 
1.3.2 Circulating tumor cells (CTCs)  
CTCs are shed from the primary tumor or areas of micro/macro-metastases and released into 
blood circulation. This motility transports CTCs to distant organs where they promote metastasis, 
with high levels of CTCs often detected in metastatic breast cancer [82, 83]. Anywhere from 1 to 
3000 CTCs may be detected in 1 mL of blood [84]. 
Researchers have heavily assessed CTCs for clinical use as there are over 17,000 
publications [85] and 10 years of large-scale clinical studies investigating their merit in cancer 
management [86]. This extensive research helped lead to the FDA approval of the CellSearch 
System™ as a prognostic tool for metastatic breast cancer. The system and the associated assay 
use EpCAM Abs to isolate CTCs from whole blood, then stains the cells for both positive 
markers using an epithelial-associated gene (CK+) and a nuclear stain (DAPI+) as well as a 
negative marker (CD45-) to differentiate the CTCs from white blood cells.  
Increased CTC levels indicate poorer prognosis and lower response to treatment for 
metastatic breast cancer patients [87-90]. Smaller studies also investigated the use of CTCs in 
non-metastatic cases for predicting likelihood of relapse [90-94]. However, clinical guidelines do 
not suggest isolating CTCs [62] in clinical practice due to the lack of actionable information 
provided from quantification alone [95]. For example, a phase III clinical trial found 
enumeration of CTCs by the CellSearch System™ to provide no benefit for high-risk patients 
when changing therapy based on the CTC results [96].  
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Analyzing CTC nucleic acid content in addition to enumeration may prove more 
impactful in the clinical setting. The CellSearch™ profile kit allows for isolation of CTCs much 
as the standard CellSearch™ system assay, but includes lysis of the cells for molecular analysis 
[95]. However, CTC tests aimed at extracting genetic material and analyzing that material are 
still not approved by the FDA. Furthermore, because the CellSearch™ system only targets 
epithelial phenotypic cells, the assay lacks inclusion of CTCs undergoing or having undergone 
EMT [97] where epithelial cells lose expression of epithelial associated genes related to cell-cell 
adhesion such as EpCAM [51] and gain expression of genes facilitating cell motility and 
degradation of the extracellular matrix such as FAPα [53]. Other CTC isolation strategies have 
proven to mitigate this issue by including mesenchymal phenotypic markers, resulting in a 
sensitivity of 100% with 90% of CTCs showing no co-expression of these markers [98]. 
1.3.3 Circulating tumor DNA (ctDNA)  
All cells release DNA into the blood stream through apoptosis or necrosis [85]. Initial discovery 
of cell-free DNA (cfDNA) indicated the presence of cancer due to higher concentrations of 
cfDNA in cancer patient blood compared to healthy individuals and a subsequent decrease after 
treatment [99]. However, other health conditions also create increased levels of cfDNA such as 
stroke, trauma, sepsis, or autoimmune disease [100]. Rather, the quantification of epigenetic or 
genetic changes such as somatic mutations, translocations, and amplifications found in ctDNA 
[101] provides more disease-specific information beneficial to breast cancer management.  
No liquid biopsy assay isolating cfDNA is currently approved by the FDA for use in 
breast cancer clinical care, though studies highlight mutational analysis of ctDNA to indicate 
therapeutic resistance. Oncogenic mutations of the ESR1 ligand have been detected in ctDNA of 
metastatic breast cancer patients diagnosed as hormone receptor (HR)+, correlating to hormone 
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therapy resistance [102-106]. The identification of resistive mutations through serial tracking of 
ctDNA could provide critical information in altering treatment [107-109]. Monitoring ctDNA 
levels may also provide actionable information before physically identifiable presence of the 
disease, having detected relapse 8-11 months before symptoms arose [110, 111]. The detection 
of heightened ctDNA levels also produced higher sensitivity for predicting treatment response 
than the CellSearch™ assay or traditional tumor markers such as CA 15-3 [112]. A higher 
abundance of mutations was also found in isolated cfDNA compared to CTCs [113], thereby 
providing larger mutant input masses for downstream PCR analysis. However, neither the 
transcriptome nor the proteome can be analyzed through ctDNA.   
1.3.4 Extracellular vesicles (EVs) 
Similar to cfDNA, most cells shed EVs into circulation [114]. Like CTCs, EVs have been found 
to play a role in the disease process by stimulating tumor growth, suppressing immune response, 
inducing angiogenesis, and contributing to the metastatic process [115-117]. CTCs and cfDNA 
have been heavily investigated in the literature as biomarkers for breast cancer, with attention 
shifted toward EVs in the last few years due to their recent discovery as a stable carrier of 
nucleic acids and proteins originating from cancer cells. 
Cancer patients have consistently produced higher concentrations of EVs [118] when 
compared to healthy individuals. However, EV enumeration alone lacks disease specificity 
because other conditions such as diabetes or cardiovascular diseases also increase their 
concentration in the blood [119, 120]. Therefore, EVs are isolated for molecular analysis of 
proteins, nucleic acids, or lipids that can provide more concise information on the nature of a 
specific disease [121, 122]. Markers of clinical significance must first be discovered in EVs as a 
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target for liquid biopsy assays before fully understanding their role as a biomarker for a specific 
cancer-related disease.  
EV-encapsulated micro RNAs (miRNAs) can differentiate cancer types and promote 
angiogenesis and metastasis [123]. Multiple miRNAs have proven to exist at higher levels in 
breast cancer patients compared to healthy individuals [124], suggesting their potential for 
detecting disease and distinguishing molecular subtypes [125]. The expression of EV proteins, 
such as fibronectin and developmental endothelial locus 1 (Del-1), may provide a venue for 
detection of early-stage breast cancer and monitor minimal residual disease post-surgery [126, 
127].  
EV membrane proteins can be targeted to enrich cancer-derived EVs, or as a disease 
marker for breast cancer detection or molecular subtype identification. Several studies have 
found that the isolation of HER2 expressing EVs through anti-HER2 Abs that can be used to 
differentiate HER2+ breast cancer patients from healthy and HER2- controls [128, 129]. The 
results aligned well with the traditional molecular analysis of HER2 protein from a tissue 
sample.  
EV messenger RNA (mRNA) has also been investigated as potential disease biomarkers 
for cancers [115, 130-132] owing to the discovery that EVs transfer host-cell mRNAs to 
recipient cells for protein translation [133]. Evidence of EV mRNA as a disease biomarker for 
breast cancer is lacking, with only one study investigating the transcriptome from metastatic 
breast cancer patients in comparison to CTC mRNA expression for monitoring therapy [134]. 
Investigating EV mRNAs for their potential use as disease biomarkers is important in breast 
cancer because gene expression profiling is currently performed on solid tissue from biopsies to 
procure further information into disease prognosis and potential therapies than is already 
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received from traditional pathology (further discussed in the molecular analysis section). 
Therefore, a need exists to investigate mRNA expression profiles from breast cancer cell derived 
EVs to determine if EV mRNA could serve as an alternative source of material extracted through 
the less invasive liquid biopsy for molecular subtyping of the disease. 
Biogenesis and structure.EVs protect and transport proteins, lipids, and nucleic acids to 
facilitate cell-cell communication, influencing functions of the recipient cell [135]. They are 
spherical and surrounded by a lipid bilayer membrane [136]. EVs are separated into three 
categories depending on their size and mechanism of release (biogenesis): exosomes, 
microvesicles, and apoptotic bodies (Figure 11).  
Apoptotic bodies range in size from 50 nm – 2 μm, microvesicles from 50 nm – 1 μm, and exosomes from 30 – 150 
nm. Adapted from Front. Cardiovasc. Med.: “Extracellular vesicles as protagonists of diabetic cardiovascular 
pathology,” by D. Gustafson, S. Veitch, and J. E. Fish, 2017, 4:71, p. 3. © 2017 Gustafson, Veitch and Fish. Adapted 
with permission under CC-BY: https://creativecommons.org/licenses/by/4.0/legalcode. Link to Publication: 
https://www.frontiersin.org/articles/10.3389/fcvm.2017.00071/full [18]. 
 
Figure 11. The biogenesis of EV subpopulations 
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Exosomes form through the collection of intraluminal vesicles (ILVs) inside 
multivesicular bodies (MVBs) and subsequent secretion by inward budding of the endosomal 
membrane [137]. They are the smallest EVs, ranging anywhere from 30 to 150 nm in diameter 
[118]. Microvesicles are generated through outward budding of the membrane and range in 
diameter from 50 to 1000 nm [136]. Finally, apoptotic bodies can form the largest size 
subpopulation, ranging between 50 and 2000 nm. They are only secreted from cells undergoing 
apoptosis, where they are released into the surrounding environment [135].  
Composition and cargo. Different EV subtypes are also similar in their composition, but do 
include distinct cargo dependent upon the physiological and pathological state of the cell of 
origin as well as the stimuli and mechanisms initiating biogenesis [136]. Little is known about 
the composition of apoptotic bodies, with most research focusing on exosomes and 
microvesicles. However, the presence of organelles may distinguish apoptotic bodies from other 
EV subclasses [138]. Further, proteins involved in the macrophage-mediated phagocytosis of 
apoptotic bodies such as annexin V, thrombospondin, and C3b serve as specific markers [139] 
found in the outer membrane. Finally, apoptotic bodies can transfer DNAs, proteins, and lipids to 
recipient cells [140-142].  
Exosomes and microvesicles share some similarity in terms of membrane and 
intercellular protein composition due to the biogenesis of these vesicles. Both EV types contain 
heat shock proteins (HSP70, HSP90) for protection from stress and regulation of protein folding, 
complex assembly, and subcellular sorting. Proteins for biogenesis (e.g. ALIX, TSG101) are 
found in both exosomes and microvesicles, but some proteins are still distinct to each EV 
subtype. Proteins for facilitating signal transduction (e.g. protein kinases, β-catenin) are 
important for transferring information within an exosome or microvesicle [136] as well as 
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through the outer membrane to recipient cells. Because the microvesicles originate in the 
cytoplasm, cytoskeletal components (e.g. actin, tubulin) and cytoplasmic material (Tau, TDP43) 
are packaged into these EVs exclusively [136]. 
Cell adhesion and intracellular trafficking facilitate the transfer of cargo to recipient cells 
and reside in the membrane of exosomes and microvesicles. In fact, many studies have used 
annexins as a method of labeling and thereby detecting EVs because they are common 
membrane proteins on all EV populations [143]. Tetraspanins facilitate the organization of multi-
molecular membrane complexes to aid in signal transduction [144]. Proteins distinct to the cell 
of origin or cell-type-specific proteins are also found within the membrane. Lipids contained in 
the membranes include phosphatidylserine and sphingolipids, with distinct lipids such as 
cholesterol and ceramides or phosphatidylethanolamine residing on exosomes or microvesicles, 
respectively. Figure 12 illustrates the molecular composition of both subtypes providing 
examples of molecules of various functions. 
Exosomes and microvesicles protect RNAs from RNase digestion occurring in the blood 
[101]. Most RNAs found in EVs measure around 200-500 nucleotides in length [136]. Derived 
from the cell of origin, EV-resident RNAs can be transferred to recipient cells to alter their 
pathology or physiology. Valadi et al. initially found miRNAs and poly-adenylated mRNAs that 
are capable of protein translation to exist in EVs [133]. More recently, RNAs including transfer 
RNA (tRNA), piwi-interacting RNA (piRNA), long non-coding RNA (lncRNA), short non-
coding RNA (snRNA), and small nuclear RNA (snoRNA) have been detected in EVs through 




Exosomes composition = top, microvesicle composition = bottom. Cargo consists of proteins, lipids, and nucleic 
acids. ALIX – ALG-2 interacting protein X; APP – amyloid precursor protein; ARF6 – ADP-ribosylation factor 6; 
ARMMs – arrestin-domain-containing protein 1-mediated microvesicles; CXCR4 – CXC-chemokine receptor 4; 
GAPDH – glyceraldehyde-3-phosphate dehydrogenase; HSP70 – heat shock 70 kDa protein; HSPG – heparan 
sulfate proteoglycan; ICAM – intercellular adhesion molecule; LBPA – lyso-bis-phosphatidyl acid; LFA1 – 
lymphocyte function-associated antigen 1; MHC – major histocompatibility complex; PECAM1 – platelet 
endothelial cell adhesion molecule; PLD – phospholipase D; PrP – prion protein; ROCK – RHO-associated protein 
kinase; TCR – T cell receptor; TDP43 – TAR DNA-binding protein 43; TFR – transferrin receptor; TSG101 – 
tumor susceptibility gene 101 protein; TSPAN – tetraspanin; VPS – vacuolar protein sorting-associated protein. 
Reprinted by permission from Springer Nature: Nature Reviews, Molecular cell biology, “Shedding light on the 
cell biology of extracellular vesicles,” by G. van Niel, G. D’Angelo, and G. Raposo, 2018, 4:19, p. 214. © 2018 
[135].  
Figure 12. General composition of exosomes and  microvesicles. 
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 Most studies find little or no amounts of full-length 18S and/or 28S RNA in EVs [133, 
146, 147], contrasting the typical abundance observed in cellular RNA. However, fragmented 
ribosomal RNA (rRNA) has been observed in multiple studies performing RNA sequencing of 
EV cargo with the rRNA accounting for at least 90% of total RNA (TRNA) found in EVs [122, 
148]. Wei et al. conducted RNA sequencing on both microvesicles and exosomes to quantify the 
levels of each RNA species from glioma stem cell lines [148]. Within the remaining 10% of 
RNA that was found to be non-rRNA fragments, only 8-25% was considered long RNA (denoted 
as >100 nt) which was further broken into coding RNA or mRNA (accounting for ≤10% of long 
RNA) and non-coding RNA [148]. It is important to note that mRNA accounted for only ~ 
0.25% of TRNA and a higher abundance of mRNA was found in microvesicles compared to 
exosomes. The other 75-92% of non-rRNA is small RNA (denoted as 15-25 nt) including 
miRNA which only accounted for about 2% and 6% of small RNA found in exosomes and 
microvesicles, respectively [148]. 
 Overall, the mechanism with which nucleic acids are packaged into EVs is still unknown, 
creating a challenge in characterizing EV RNA [136]. Furthermore, the EV source, data 
collection modality, and isolation procedure contribute to the final resultant RNA quantification 
and characterization. Therefore, it is important to develop robust EV isolation methods to 





Chapter 2. Development of EV-MAP for breast cancer management 
2.1 Introduction 
This study aimed at investigating a less invasive method of isolating mRNA from breast cancer 
patients through a liquid biopsy biomarker, as mRNA is used for the intrinsic subtyping of breast 
cancer cases to provide further information into disease prognosis and potential treatment 
pathways than is received from traditional pathology. EVs are ideal for this purpose as they are 
stable carriers of mRNA within the blood. Once deciding upon a biomarker, it is next important 
to determine how these EVs will be isolated. As previously stated in the EV composition section 
of Chapter 1, the isolation method may affect the downstream analysis of EV internal cargo. 
With many isolation methods currently available, it is important to understand the advantages 
and limitations of each in order to choose the technique most beneficial for the specific 
downstream application of EVs, such as gene expression analysis of disease-associated EVs in 
the case of this study. 
2.1.1 EV isolation 
Benchtop methods. The traditional and most common technique for EV isolation is differential 
ultracentrifugation. This procedure separates EVs from cells or proteins based on size and 
density. Culture media or whole blood is centrifuged at 300g for 10 min to remove cells followed 
by 2,000g for 10 min to remove most apoptotic bodies, dead cells, and cell debris. A step at 
10,000-14,000g for 30 min pellets most larger microvesicles [149], which may be resuspended 
for separate analysis from exosomes still remaining in the supernatant [150, 151]. Several 
subsequent steps of ultracentrifugation at 100,000-110,000g aim to purify the exosomes of any 
contaminating proteins.  
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Sucrose gradient centrifugation can further purify exosome fractions by eliminating 
sedimented proteins [149]. EVs remain in the gradient while contaminants sink to the bottom. 
Though differential ultracentrifugation is still the EV isolation gold standard, it fails to enrich 
certain subpopulations of EVs because it only isolates particles <150 nm [152]. Further, the 
laborious process may take 5-12 hours, requires expensive equipment often difficult to access, 
and results in a recovery of up to 60% even from a non-complex sample such as culture media 
[153].  
Precipitation techniques decrease processing time and cost, with many commercial kits 
available using polyethylene glycol (PEG). These kits isolate EVs within 30 min after use of a 
centrifugation step at 10,000g [118]. PEG is an agglutinating agent [154] that reduces the 
solubility of EVs <250 nm [153] while keeping proteins in the aqueous phase. PEG precipitation 
improves EV recovery compared to differential centrifugation, isolating up to 90% of EVs [153]. 
However, studies have shown relatively low purity in EV fractions compared to those isolated 
through differential ultracentrifugation [155-157] due to proteins stuck in the PEG matrix and 
thereby pelleted with EVs. 
 Performing microfiltration before differential ultracentrifugation saves time by removing 
cells and larger EVs [158, 159]. Commercially available ultrafiltration membranes separate 
exosomes from smaller proteins, rendering any centrifugation steps unnecessary [153]. However, 
clogging by contaminants or trapping of EVs produces low EV yields [154] in comparison to 
centrifugation. Filtration as an additional step before size-exclusion chromatography clears the 
biological fluid of larger particles [160, 161]. During size-exclusion chromatography, smaller 
proteins reside in the stationary phase while EVs elute more quickly (Figure 13) [118]. 
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Appropriate selection of the matrix and accurate timing of elution collection are critical to the 
success of this isolation procedure.  
None of the methods previously stated exclusively isolate cancer-derived EVs from the 
normal EV background, which could confound disease specific genetic signatures in downstream 
analysis. For example, isolation of glioblastoma patient EVs through differential 
ultracentrifugation resulted in lower mRNA expression of a tumor-specific gene EGFRvIII and 
created a higher background of GAPDH housekeeping gene, suggesting that size-based methods 
of EV isolation confound the expression of genes derived from disease-associated EVs [162]. 
Little consensus is provided within the literature for the number of EVs found in healthy 
individuals due to discrepancies between various isolation and enumeration techniques. 
However, to give an understanding of the EV background found in healthy individuals, ~ 
107[163] to 109 [164] EVs are found in 1 mL of healthy plasma, with 50% of these EVs 
originating from either platelets or erythrocytes [163].  
The pores in the gradient preferentially trap the smaller proteins, causing EVs to elute faster and in a separate 
fraction. Reproduced from Biovision Incorporated, 2019, retrieved from https://www.biovision.com/e 






Figure 13. Illustration outlining size exclusion chromatography (SEC) for isolation of EVs. 
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Immunoaffinity isolation serves as a method of mitigating background EVs confounding 
disease-related expression signals by selecting EVs through antibodies (Abs) bound to a surface, 
such as the surface of microbeads. For example, affinity-decorated microbeads can be incubated 
with the biological sample for time periods ranging from 1 to 4 h [165], then require post-
processing steps such as magnetic separation and centrifugation to yield the final purified EV 
fraction. The antibody may select the general EV population by targeting tetraspanins (e.g. 
CD81, CD63, or CD9), or subpopulations derived from targeted cell types required for a specific 
clinical application. Researchers have targeted cell-specific markers for enriching EVs from a 
cancer origin [156, 166, 167], with one study using anti-HER2 Abs for the isolation of cancer-
derived EVs from human breast cancer patients [168].  
Immunoaffinity isolation produces highly enriched fractions of disease-associated EVs, 
as was shown in the average 10-fold increase of EV-associated proteins from immunoaffinity 
microbeads selecting for EpCAM from colorectal cancer EVs in comparison to differential 
ultracentrifugation which resulted in a higher protein concentration, but lower enrichment of EV-
associated proteins [156]. Immunoaffinity isolation of EVs has also proven to enrich EVs from 
ovarian cancer patient serum compared to healthy controls, amounting to detectable levels of 
miRNA from the anti-EpCAM isolated EVs from patient serum while the healthy serum 
produced no detectable miRNAs [169]. However, immunoaffinity isolation using microbeads 
may result in low purity with one study finding a 15-fold enrichment of the common plasma 
protein albumin from anti-EpCAM microbead isolated EVs when compared to differential 
ultracentrifugation with a sucrose gradient [170]. 
   Each benchtop technique includes complex workflows comprised of multiple steps 
potentially requiring expensive equipment and experienced operators. Microfluidics may 
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improve upon these limitations by rapidly isolating EVs from small volumes (50 µL – 1 mL) on 
a single platform capable of performing multiple processing steps, thereby decreasing target loss 
or contamination risks [118]. Some technologies also integrate both EV enrichment and 
proteome or transcriptome analysis into one device through on-chip immunofluorescence assays 
or PCR, further simplifying the workflow and potentially eliminating the need for expert 
operators making EV-based assays more accessible. 
Microfluidics for EV isolation.  Many researchers have applied microfluidics to isolate EVs. 
Some platforms take advantage of size-based isolations by incorporating unique geometries to 
either direct the flow of EVs away from contaminants or directly capture EVs on the device. For 
example, microfluidics employing microfiltration as an isolation strategy [171, 172] may include 
a double-filtration set-up for initial large EV removal followed by a smaller pore membrane to 
eliminate proteins while capturing exosomes within the filter (Figure 14A) [173, 174]. Novel 
size-based sorting techniques not amenable to benchtop operation have also been used including 






(A) Schematic of the Exodisc double-filter device (top), with a cross-sectional illustration of the EVs journey 
through the two filters. Reprinted with permission from “Exodisc for rapid, size-selective, and efficient isolation 
and analysis of nanoscale extracellular vesicles from biological samples,” by Woo et al., 2017, ACS Nano, 11:2, p. 
1361. © 2017 American Chemical Society [165]. (B) Schematic of a ciliated micropillar array showing the passage 
of cell debris and proteins, with exosomes trapped in the wires. The panel below shows the (a) silicon nanowires 
(200 nm scale bar), (b) micropillars (2 µm scale), and (c) fully assembled ciliated micropillars. Reprinted with 
permission of The Royal Society of Chemistry, from “Ciliated micropillars for the microfluidic-based isolation of 
nanoscale lipid vesicles,” by Wang et al., 2013, LOC, 13:15, p. 2880.© 2013; permission conveyed through 
Copyright Clearance, Inc. [167]. (C) Application of the acoustic field concept illustrated in (D) with fluorescently 
labeled particles of different sizes injected. The larger particles are pushed toward the sides (1 µm). Adapted with 
permission from “Acoustic purification of extracellular microvesicles,” by K. Lee et al., 2015, ACS Nano, 9:3, p. 
2322,2324. © 2015 by American Cancer Society [170]. (E) Scanning electron microscope image of a nano-DLD 
sorting array with many of these pillars fabricated in the Nano-DLD array section of the device in (F), showing the 
schematic (left) and operation (right) of a nano-DLD device. Larger EVs displace laterally to congregate in the 
“fully bumped channel” while smaller exosomes follow the straight path through the device. Reprinted by 
permission from Springer Nature: Nature Nanotech, “Nanoscale lateral displacement arrays for the separation of 
exosomes and colloids down to 20 nm,” by B. H. Wunsch et al., 2016, 11:11, p. 937,939. © 2016 [174].  
Figure 14. Microfluidics for size-based EV isolation 
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Nanowires trap EVs much like filters but are placed vertically on micropillars and can 
dissolve in a solvent for EV release [175-177] (Figure 14B). Applying an acoustic field across a 
fluidic channel forms a force gradient that differentially effects particles based on their size, 
density, and compressibility to enrich EVs from a sample [178-181] (Figure 14C, D). This 
method eliminates clogging that may occur through trapping techniques. DLD separates particles 
using an array of different pillar geometries, forcing particles to move streamline or laterally 
based on their size. Particles with a diameter larger than the pillar spacing will displace 
horizontally, while smaller particles follow the flow path [182, 183] (Figure 14E, F). EVs of 
varying sizes will experience differing elastic lift forces when flowing through a viscoelastic 
medium, pushing large EVs toward the center and leaving exosomes along the channel sidewalls 
[184]. However, this approach needs further investigation using complex biological fluids. 
 Size-based microfluidic isolation methods incur similar shortcomings to benchtop 
methods in their inability to selectively isolate disease-associated EVs. However, these 
techniques could provide benefit in the research and study of EV biology and physiology by 
enriching all EV subpopulations. Immunoaffinity isolation techniques must be employed when 
isolating disease-specific EVs in order to prevent the loss of disease-related mRNA or miRNA 
expressions because of a large background of EVs (see immunoaffinity section of bench top 
techniques for further discussion) [162]. 
 Microfluidics may use microbeads containing surface-immobilized antibodies as 
demonstrated on the benchtop using magnetic beads or direct attachment of antibodies to the 
surface of a microfluidic device. Integration of microbeads into a microfluidic platform may 
eliminate handling steps, therefore decreasing the risk of contamination and complexity of the 
assay compared to benchtop immunoaffinity techniques. However, microfluidics requiring 
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incubation of sample and beads off-chip for isolation offer little benefit in decreasing operator 
steps or assay time. Coupling initial sample preparation to a device that can perform on-chip 
analysis of target molecules such as proteins mitigates this limitation by decreasing handling 
steps post-processing [129, 185, 186]. Researchers have also developed microfluidic devices 
with internal incubation (Figure 15A,B) [187], facilitated by on-chip mixing and microbead 
trapping [188, 189]. Immunoaffinity capture through microbeads provides a large surface area-
to-volume ratio for potential high loads of EVs. However, microbeads add cost to the assay and 
may still require long incubation times, potentially leaving direct surface modification as a more 
viable alternative. 
 Surfaces of microfluidic devices may be immobilized with antibodies through coupling 
reactions, such as EDC/NHS or avidin/biotin [95]. Chen et al. initially demonstrated surface 
modification for isolating EVs in a straight microchannel populated with herringbone grooves to 
facilitate convection, increasing EV interaction with the device surfaces to improve recovery 
[190]. Another device immobilized antibodies on a mica surface to capture EVs for subsequent 
AFM analysis [191]. Kanwar et al. used reservoirs serially attached through small microchannels 
to increase the recovery of EVs by increasing residence time (Figure 15C-E) [192]. These 
devices were only optimized and developed through pan-EV markers, such as tetraspanins for 
isolation of all EV subpopulations. Therefore, they did not provide evidence for the ability to 





(A) Schematic of the immunomagnetic exosomal RNA (iMER) platform. Scale bar is 1 cm. (B) Average higher 
mRNA copies of three genes associated with glioblastoma were observed in the patient samples compared to 
healthy controls. Reprinted from Nat. Comm.: “ Chip-based analysis of exosomal mRNA mediating drug 
resistance in glioblastoma,” by Shao et al., 2015, Vol. 6, p. 3, 7. © 2015 Macmillan Publishers Limited. With 
permission under CC-BY: https://creativecommons.org/licenses/by/4.0/legalcode. Link to publication: https://ww 
w.nature.com/articles/ncomms7999#additional-information [178].(C) The ExoChip design. 5 mm diameter (D), 9 
mm spacing (P), 73 mm length (L), and 100 µm height (H). These reservoirs are connected through narrower 
channels featuring a width of 0.75 mm (W). The anti-CD63 immobilized extracellular vesicles were stained with 
DiO, then quantified using the encircled areas to calculate fluorescence intensity collected from fluorescence 
microscopy images. (D) The reservoirs infused with pancreatic cancer samples (D) show higher concentration of 
EVs than the healthy (H) samples, with little fluorescence present in the non-specific light chain’s 
immunoglobulin (LC-IgG) control (C). (E) Protein expression levels of the isolated EV populations were then 
calculated using densitometry analysis in image J. The plot shows relative densities for the control (C), healthy 
(H), and disease (D) samples. The brackets indicate fold change in expression levels between the diseased (D) and 
healthy (H) EVs. Reproduced with permission of The Royal Society of Chemistry, from “Microfluidic device 
(ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes,” by S. S. Kanwar, C. 
J. Dunlay, D. M. Simeone, and S. Nagrath, 2014, LOC, 14:11, p. 1892, 1897. ©2014; permission conveyed 
through Copyright Clearance Center, Inc. [183]. 
Figure 15. Microfluidic immunoaffinity isolation of EVs. 
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Recent microfluidic devices have selectively targeted host-cell specific EVs to investigate 
the clinical relevance of these biomarkers. Most have modified the surface within the 
(A) Schematic of the nano-interfaced microfluidic exosome platform (nano-IMEX), made of glass/PDMS coated 
with graphene oxide (GO)-induced, nanostructure polydopamine (PDA) film. The scheme also highlights Y-shaped 
microposts built on the surface. (B) The PDA-induced 3D nanostructuring through an intial GO coating for 
attachment of proteins and antibodies subsequently attached. (C) Ovarian cancer samples produced a fluorescence 
intensity significantly higher (***p < 0.001) than that found from healthy controls. Reprinted from The Royal 
Society of Chemistry: “ Ultrasensitive microfluidic analysis of circulating exosomes using a nanostructured 
graphene oxide/polydopamine coating,” by P. Zhang, M. Hei, and Y. Zeng, 2016, LOC, 16:16, p. 3034, 3040. © 
2016. Permission under the CC BY-NC: https://creativecommons.org/licenses/by-nc/3.0/legalcode. Link to 
publication: https://pubs.rsc.org/en/content/articlehtml/2016/lc/c6lc00279j [184]. (D) Microscopy images showing 
successful capture of fluorescently labeled EVs in the herringbone channels through selective isolation using 
cetuximab (large under-layed image, scale bar 50 µm), anti-EGFRvIII (left insert), or a cocktail of both (right 
insert). (E) Signals of EVs from glioma cells encoding either palmitoylated-tdTomato (red) or -GFP (green). Scale 
bar 1 µm. (F) Healthy plasma EVs captured produced no EGFRvIII copies, delineating them from the glioblastoma 
samples. EVs were isolated using an antibody cocktail, and copy numbers were normalized to sample input. 
Reprinted from Nature Comm.: “Engineered nanointerfaces for microfluidic isolation and molecular profiling of 
tumor-specific extracellular vesicles,” by Reategui et al., 2018, 9:1, p. 3,6. With permission under CC-BY: 
https://creativecommons.org/licenses/by/4.0/legalcode. Link to publication: https://www.nature.com/articles/s41467-
017-02261-1#rightslink [185]. 
 
Figure 16. Surface modification with 3D nanostructuring for isolation of EVs. 
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microfluidic to maximize recovery without increasing the device footprint. Zhang et al. used a 
coating of nanopores created through a layer-by-layer deposition of graphene oxide and 
polydopamine to increase capture surface area while a Y-shaped microstructure facilitated 
mixing for EV-surface interactions [193] (Figure 16A-C). This technology selectively detected 
ovarian cancer-derived EVs using anti-EpCAM selection. The herringbone device previously 
developed by Chen et al. [190] was modified from its original design to include layer-by-layer 
deposition of functionalized nanopores to increase the recovery of glioblastoma-derived 
EVs[162] (Figure 16D-F). Another microfluidic composed of nanohole arrays functionalized 
with anti-EpCAM and anti-CD24 antibodies on a gold surface specifically captured ovarian 
cancer cell-derived EVs [121]. 
Though several microfluidic devices have been developed for the immunoaffinity capture 
of EVs through surface modification, they often lack definition of performance parameters, such 
as recovery, purity, and EV load (Table 5). The high recovery and purity of EV fractions from 
biological samples is extremely important when using them for downstream proteome, 
transcriptome, or genome analyses. 
Further, many of the aforementioned technologies are based on complex and time-
consuming fabrication methods and thus, do not coincide with high-scale manufacturing to 
accommodate clinical applications that demand one-time use devices. Therefore, a need exists 
for a high purity, high recovery, and high yield EV isolation platform whose fabrication is low 
cost for accommodating large-scale clinical studies to facilitate the discovery of EV-associated 
biomarkers for use in cancer liquid biopsies. Further, only a few microfluidic devices have been 
applied for isolation of EV RNA for mRNA expression analysis and was implemented in 
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glioblastoma patient samples [121, 162], highlighting another need for new microfluidic 
technology geared toward isolation of EVs for internal cargo assessment.  








Recovery Purity Ref. 
Nanowire 
trapping 
Size NR 10 10% NR [175] 
Membrane 
filtration 
Size 4x1010 20 65% 





Size 1.47x1011 36 95.7% 





Size NR 33 74.2% 













Size NR 2.13 39% 




























Viscoelastic flow 3x1010 ~3 93.6% 
>90% purity of 
particles <200 nm 









~5x1011 2 NR NR [186] 














NR 4 >93% 
<5% nonspecific 
binding on isotype 
control 
[187] 
NP refers to nanoparticles as some studies only used polystyrene beads or liposomes for characterization. NR 
means the value was not reported. Adapted from “Microfluidics for exosome isolation and analysis: enabling 
liquid biopsy for personalized medicine,” by J. C. Contreras-Naranjo, H. J. Wu, and V. M. Ugaz, 2017, LOC, 




Herein, an in vitro device for extracellular vesicle microfluidic affinity selection (EV-
MAP) was developed which addresses the limitations stated above. The mechanism of isolation 
is immunoaffinity selection in order to capture only disease-associated EVs so any background 
EVs cannot mask or confound mRNA expression or expression differences between genes, as 
has occurred with implementing size and density-based technologies [162]. The EV-MAP device 
uses surface modification of mAb because it mitigates the need for time-consuming preparation 
steps and expensive microbeads which do not align well with the goal of creating a low cost one-
time use disposable device. Further, as is also seen for the benchtop application of microbeads, 
microfluidic microbead assays often result in low purity (as seen in Table 5) when compared to 
surface modification. 
 EV-MAP is produced using a simple fabrication process of imprinting a pattern from a 
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production such as injection molding. Because these devices are made out of plastic, they are 
produced at low cost which makes them appropriate for one-time use in in vitro liquid biopsy 
tests unlike a majority of the microfluidics listed above (Table 5). The device consists of 
micropillar arrays which facilitate mAb-EV interactions by decreasing the diffusional distance 
required for EVs to come in contact with a mAb-conjugated surface to increase recovery and 
yield when compared to other surface modification microfluidic platforms (see Table 5), with 
many not even reporting on these parameters. Two forms of the EV-MAP device exist: one with 
three beds populated with micropillars set up in series while the other holds seven beds 
processed in parallel which creates a ~ 5-fold increase in surface area and consequently EV load. 
In this study, the three-bed design of EV-MAP was used. 
The EVs isolated from the EV-MAP device are then lysed for transcriptome analysis 
through mRNA expression profiling, aligning the technology with analysis currently used in 
clinics for identifying molecular subtypes of breast cancer. This highlights the importance of 





2.2.1 EV-MAP device fabrication and design  
Fabrication procedure.The fabrication procedure is summarized in Figure 17A, with a diagram 
flow of the process in Figure 17B. The brass metal mold master was fabricated using high 
precision micromilling (KERN 44, KERN Micro- und Feinwerktechnik GmbH & Co.KG; 
Murnau, Germany) from a 100 µm milling bit (Precision Micro Tool). The 3” master contained 
two EV-MAP devices, each containing 3 beds with an array of 15,202 holes and inlet and outlet 
ports for capillary connections (365 µm OD, 150 µm ID, Polymicro Technologies). The EV-
MAP device was embossed into 6013S-04 cyclic olefin copolymer (TOPAS Advanced 
Polymers) using the mold master at 162° C with 900 lb. of force using a precision press (Wabash 
MPI), with the replicated devices demolded at 150° C. A full cycle time for replication took 12 
min. Mold release agent (MoldWiz® F57-NC), provided by Axel Plastics, kept plastic from 
sticking to the mold master. 
The devices were then taped to cover channels and protect them from any debris 
produced while cutting them apart (Skil, 120V, 9-inch bandsaw). The tape was removed 
followed by sonicating the devices in 10% Micro-90® (Sigma-Aldrich). Subsequent rinsing with 
reagent-grade isopropyl alcohol (IPA, Fischer Scientific) and nanopure water was performed 




The device channels were sealed by annealing a 250 µm COC cover plate to the device. 
A similar procedure involving 10% micro-90, IPA, and nanopure water cleaned the cover plates 
(A) Process flow with pictures showing the EV-MAP device and equipment used at every fabrication step. The red 
circles indicate the epoxy capillary connections. (B) Diagram showing the process flow from brass mold fabrication 
using a high precision micromill to allow for high aspect ratios and micrometer dimensions, imprinting of the 
pattern from the mold to the COC plastic through hot-embossing for device replication,  UV/O3 irradiation 
treatment, and thermal fusion bonding to seal the microchannels to the cover plate. 
 
Figure 17. Fabrication procedure for the three-bed EV-MAP device. 
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before being placed in a drying oven. Both the cover plates and devices were UV/ozone 
irradiated for 13 min at 27 mW/cm2 (measured at 254 nm wavelength) in a Model 18 UVO-
Cleaner® (Jelight Company). Glass capillaries with a 150 µm ID (365 µm OD, Polymicro 
Technologies) were positioned at the outlet and inlet ports of the UV/O3 modified device, with a 
cover plate placed over the top of the assembly (UV/O3 modified side facing the channels). The 
assembly was secured between two glass plates clamped in position with alligator clips to apply 
adequate pressure to facilitate thermal fusion bonding (HeraTherm OGS60 General Protocol 
Oven, Gravity Convection, 2.3 Cu.Ft. 120V, Thermo Scientific) for 1 h at 134 °C. The capillary 
ports were then sealed with epoxy (Loctite® EA 9017, Henkel) after annealing to keep devices 
from leaking.  
EV-MAP device design.The three-bed EV-MAP device contained three serially connected beds 
(Figure 18A) populated with circular micropillars (Figure 18B). The high precision micromill 
created a 4.6° draft angle in the holes of the brass master mold from the drilling bit, transferring 
this slope along the 92 μm height of the micropillars. This caused a gradient of pillar diameters 
from 110 μm at the top to 120 μm diameter at the bottom and with an approximate 10 µm pillar 
spacing (Figure 18C) along the pillar shaft. The small interpillar spacing relative to the pillar 





Table 6. List of device dimensions for the three-bed EV-MAP. 
Dimension Value 
Pillar height 92 ± 3 μm 
Pillar diameter 109 ± 3 μm 
Inter-pillar spacing 10 - 20 μm 
Draft angle 4.6° 
Total bed length 122 mm 
Number of pillars 15,202 
Surface area 7 cm2 
Internal volume 7 μL 
 
2.1.2 EV-MAP surface modification 
Soper et al. has previously applied UV/O3 irradiation to activate thermoplastic surfaces [194]. 
The UV exposure and oxidative stress simultaneously create O3 molecules that break bonds to 
form free radicals, while also forming free radicals in the plastic that may fragment or crosslink 
polymer chains [195]. The free radicals may then react with other free radicals in the polymer to 
form carboxylic acid groups on the surface. Previous studies have investigated the use of UV/O3 
Image of the fully assembled device, CAD schematics illustrating the serial connection of three beds, each 
containing micropillars to form high aspect ratio microchannels as shown from Keyence laser scanning 




EV-MAP assembled device 
Embossed 
device 
Figure 18. Computer aided drawings (CAD), microscopy images, and photo of the three-bed EV-MAP device. 
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irradiation on COC, with results showing successful creation of carboxylic acid groups [195, 
196].  
Covalent coupling reactions were then used to chemically attached mAbs to the 
carboxylic acid surface groups. The covalent coupling reaction uses EDC (1-Ethyl-3-(3-
dimethylaminopropyl)-carbodiimide) and NHS (N-hydroxysuccinimide) to react with the 
carboxylic acid groups (-COOH) to form a succinimide ester intermediate that subsequently 
reacts with primary amine groups found on the mAbs. EDC/NHS coupling has been used to 
immobilize mAbs to the surfaces of thermoplastic microfluidic devices in the past [197, 198], 
including devices fabricated in COC [98, 194]. The EDC/NHS coupling procedure used for the 
EV-MAP device was slightly modified from the protocol established by Witek et al. for CTC 
isolation [98], as acetonitrile (ACN) was the solvent used during the reaction instead of MES 
buffer because it is a dry organic solvent and would therefore minimize any hydrolysis that could 
occur. This modified procedure is shown in Figure 19. 
Twenty mg/mL of EDC was combined with 2 mg/mL of NHS and dissolved in dry 
reagent-grade anhydrous ACN through vigorous vortexing. Then, this mixture was immediately 
injected into an assembled device and incubated at room temperature for 25 min. Ten µL of 
nuclease-free water displaced the ACN before injecting the mAb to mitigate precipitate 
formation due to mAb reconstitution in PBS buffer (0.68 mg/mL in PBS, pH = 7.4). The devices 
were incubated at room temperature for 2 h before being placed in a 4°C refrigerator overnight. 
If devices were not used the next day, they were stored for up to 1 month at 4°C in a Protein 




The efficiency of the EDC/NHS coupling reaction was analyzed through parallel 
immobilization of a 5’ -amino, 3’ -Cy5 oligonucleotide linker (5’ -NH2-C12-
T8CCCTTCCTCACTTCCCTTTUT9-Cy5; HPLC-purified, 1 mM stock solution in nuclease free 
water and diluted to 10 µM with PBS; Integrated DNA Technologies) during each mAb 
immobilization procedure (Figure 20A, B). The oligonucleotide functionalized devices were 
washed with 0.1% sodium dodecyl sulfate (SDS, Life Technologies) (25 µL/min, 40 min) then 
displaced with ≥200 µL PBS (pH 7.2). The oligonucleotide-immobilized device was imaged 
with a 200M inverted microscope (Zeiss) using a 10X objective (0.3 NA, Plan NeoFluar), XBO 
After UV/O3 irradiation of the devices, carboxylic acid groups are formed on the surfaces. These carboxylic acid 
groups (-COOH) serve as anchors for the EDC/NHS-mediated immobilization. Twenty mg/mL of EDC and 2 
mg/mL of NHS were dissolved in ACN buffer and quickly infused into the EV-MAP devices. During the 25 min 
incubation period, the EDC forms an o-acylisourea through binding with the carboxylic acid group. This 
intermediate is quickly replaced by the NHS to form a more stable NHS ester. Devices are then quickly flushed 
with nuclease-free water then infused with mAb. These mAbs conjugate with the carboxylic acid groups through 
their primary amine group, attaching them to the COC device surface for capture of EVs expressing the antigen of 
interest. 
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Figure 19. Process flow and reaction chemistry of the EV-MAP mAb conjugation reaction. 
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75 Xe arc lamp, single band Cy5 filter set (Omega Optical), Cascade 1K EMCCD 
(Photometrics), and MAC 5000 stage (Ludl Electronics Products). These images were then 
background subtracted and analyzed using a custom macro (Appendix A1) input into Image-J 
software. Comparison of the intensity values showed a significant difference between the 
EDC/NHS and ACN control (p < 0.00001 for 95% confidence under two-tailed t test; Figure 
20B). 
Anti-EpCAM (clone 158210), anti-FAPα (clone 427819), and anti-CD81 (clone 454720) 
mAbs were used in these studies. Isotype controls were also employed for investigation of assay 
specificity using the anti-EpCAM isotype IgG2A (clone 20102) or the anti-CD81 isotype IgG2b 
(clone 20116). Devices were only modified with one type of mAb. All mAbs were secured from 
R&D Systems and derived from mice. 
  
(A) Fluorescence microscopy images taken with a Cy5 filter on a 200M inverted Zeiss microscope after EDC/NHS-
modulated immobilization of the 5’-NH2 oligonucleotide fluorescent reporter used to verify successful EDC/NHS 
coupling for mAb immobilization. The positive control (image on the left) included EDC/NHS in ACN buffer, 
while the nonspecific control (image on the right) was treated identically but with only ACN buffer infused into the 
chip without the EDC or NHS reagents. Images are background subtracted, intensity scaled, and were imaged 
through a 10X objective. (B) Quantitative analysis of 9 images taken from either a single positive (EDC/NHS) and 
negative (ACN only) control device. Error bars correlate to these 9 images taken in 9 different locations on a single 
device. P < 0.00001 under a two-tailed t test. 
 




















Figure 20. Immobilization efficiency of the EV-MAP EDC/NHS coupling reaction. 
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2.1.3 Sample preparation 
Cell line media for EV-MAP characterization. MCF7, Hs578T, and SKBR3 cells were 
collected from ATCC, kept in liquid nitrogen, and cultured in 5% CO2 at 37° C for ≤30 passages. 
Culture media consisted of MEM alpha (Gibco)/10% Fetal bovine serum (FBS, Performance, 
Gibco) augmented with 1 µL human insulin (Sigma)/mL MCF7 media, HydroClone™ DMEM 
high glucose (GE Life Sciences)/10% FBS for Hs578T cells, and McCoy’s 5A (Corning)/10% 
FBS for SKBR3 cells. EVs secreted from FBS were removed by ultracentrifugation (100,000g, 
18 h, 4° C) using an L8-80M ultracentrifuge (Type 45 Ti roto, 38 mm x 102 mm (70 mL) 
polycarbonate tubes; Beckman Coulter), and mechanical Harvard Trip balance (OHAUS). Tubes 
were sterilized with 10% hydrogen peroxide and cleaned with Virkon S (Dupont) when retrieved 
from the ultracentrifuge and carried to the culture hood. FBS was decanted, mixed thoroughly, 
aliquoted, and kept at -20° C. To extract EVs, cell lines were transferred to EV-depleted FBS-
containing media and conditioned for one week, with the media decanted once cell lines reached 
90% confluency. The cell lines were then centrifuged at 2000g for 10 min after decanting the 
media.  
Plasma samples for EV-MAP characterization.  Donor samples used in optimization studies 
of the EV-MAP assay were obtained from Bioreclamation IVT. Blood was collected from a 
donation center, freshly centrifuged to obtain plasma, immediately frozen, and shipped. The 
donors were tested for the presence of any infectious diseases such as HIV, but no other 
information about current health or health history was documented. Two samples came from 
female donors and two samples from male donors, with ages ranging from 46 to 55 years. The 
plasma samples were stored at -80° C until processed. 
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 Healthy control samples were received from the University of Kansas Medical Center 
(KUMC). Blood was collected from women arriving at KUMC for routine mammograms, 
therefore ensuring no diagnosis or signs of breast cancer. Blood was stored in EDTA and 
immediately delivered, then centrifuged at 300g for 10 min, followed by two centrifugations at 
2000g for 10 min with the plasma stored at -80° C until processed using the EV-MAP assay. 
Breast cancer patient plasma samples were obtained from KUMC’s Biospecimen 
Repository Core Facility (BRCF). All plasma samples were collected in 2017 and stored in 
liquid nitrogen until transported to the laboratory and stored at -80° C. Patient samples were also 
received from the University of Kansas Cancer Center’s Indian Creek location. These samples 
were collected in the Spring of 2019, immediately centrifuged following the blood draw at 300g 
and twice at 2000g for 10 min to extract the plasma, and then stored at -80° C until processed 
using the EV-MAP device. 
 All patient samples were from women, with most ranging in age from 55-60 years old. 
Two patients were diagnosed with either ductal carcinoma in situ (DCIS) or invasive mammary 
carcinoma (IMC), with the rest diagnosed with invasive ductal carcinoma (IDC). Most samples 
were collected after some form of therapy was already administered. Table A2 in the appendix 
summarizes both demographic and clinical information for all patients.  
EV-MAP sample processing. Blocking buffers were filtered through a 0.22 µm PTFE syringe-
fitting filter (Fisher Scientific) immediately before infusing 400 µL into the mAb-modified 
devices at 10 µL/min. All infusion steps were performed with a multi-channel New Era syringe 
pump using 1 mL syringes (BD). Devices were kept on ice during the blocking step. Plasma or 
conditioned media infusion occurred at room temperature with a volumetric flow rate of 2.1 
µL/min, because this flow rate showed the highest recovery while still allowing time after 
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infusion for EV lysis within the same day to minimize TRNA degradation. The eluted sample 
volume was collected in microcentrifuge tubes and weighed to determine the true volume 
processed based on the measured fluid density. The devices were then placed on ice and rinsed 
with 400 µL of washing buffer at 10 µL/min. After the devices were washed, the EVs isolated on 
the surfaces were either released for EV enumeration, size characterization, and microscopy 
analysis, or directly lysed on-chip for EV mRNA expression profiling. 
2.1.4 EV release from capture surface.  
EVs were released from EV-MAP devices for nanoparticle tracking analysis (NTA) and 
transmission electron microscopy (TEM). Devices were manually infused with 60 µL of 0.2% 
proteinase K in PBS (or 0.05% trypsin/ 0.53 mM EDTA in certain cases), enclosed in a vacuum-
sealed bag, and submersed in a water bath at 37°C for 30 min. The vacuum-sealed bag was then 
sonicated for 10 min at room temperature to mechanically disrupt any EVs physically adsorbed 
to the surface. Released EVs were eluted into 350 μL of PBS (10 μL/min), then stored at -80°C 
until performing NTA or TEM.  
NTA. EV samples were heavily vortexed to homogenize each replicate, loaded into a 1 mL 
syringe (BD) and introduced into the flow cell of a NanoSight LM10 NTA instrument (Malvern 
Panalytical) equipped with either a 405 nm laser and NTA 3.2 software or a 488 nm laser and 
NTA 2.3 software. If the sample concentration fell outside the dynamic range of the instrument, 
the sample was diluted to 10-100 EVs per frame. A camera shutter of 1206, camera gain 366, 90-
160 s acquisitions, and five averaged replicates were used to image the samples. Between images 
while the camera was turned off, the sample was manually advanced by ~25 µL to measure 
random portions of the sample for each replicate.  
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All processing used the Detection Threshold 5. After maintaining 5 replicates for a single 
sample, the flow cell was rinsed with 1 mL PBS then infused with air four times. The flushing 
procedure was validated by visually monitoring the number of nanoparticles observed in 300 µL 
PBS (~0-1 per 100 µL). Particle concentrations were normalized to the total sample volume 
processed through the devices. 
TEM. TEM grid preparation procedures were adapted from Théry et al. [199]. Ten µL of sample 
was placed on copper grids (Carbon Type-B, 200-300 mesh, Ted Pella) and incubated for 20 min 
while covered with parafilm to keep them from drying out. Each grid was rinsed with 100 µL of 
water eight times for the duration of 2 min each. After washing the grids, the sample was stained 
with 50 µL uranyl acetate (0.4% w/v, pH 4, filtered through 0.22 µm). The grids were then 
blotted on filter paper to remove any unabsorbed staining reagent and placed in a grid holder 
until TEM was performed.  
2.1.5 EV mRNA profilingEV or cell lysis for extraction of TRNA. EVs were lysed directly 
from EV-MAP devices by injecting 100 µL TRI Reagent® (Zymo Research), which was 
collected in microcentrifuge tubes. The devices were incubated at room temperature for 5 min 
and infused with another 100 µL of TRI Reagent®. Any remaining fluid in the devices was then 
displaced with air. In certain cases, TRNA was extracted directly from cells by resuspending the 
pellet in 300 μL of TRI Reagent® through vortexing after centrifuging cell culture media at 300g 
for 10 min.  
TRNA purification and reverse transcription. TRNA was purified following the 
manufacturer’s protocol for the Direct-zol Microprep kit (Zymo Research) and eluted in 6.5 - 8.5 
µL of nuclease free water for EV-TRNA or 8 - 10 μL of nuclease free water for cell TRNA. Two 
µL of purified TRNA was subsequently analyzed with a 2200 TapeStation and high sensitivity 
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RNA tape, buffer, and ladder (Agilent Technologies) according to the manufacturer’s procedure. 
Though the electrophoresis conditions for the high sensitivity tape are unknown, it is probably 
run on a 3% denaturing agarose gel at 5 V/cm and samples loaded with formaldehyde loading 
buffer including 0.4% bromophenol blue and xylene cyanol. Less than 1 µg of cell-derived 
TRNA or 2 µL of EV-TRNA was reverse transcribed into complementary DNA (cDNA) through 
the ProtoScript® II First Strand cDNA Synthesis Kit (New England Biolabs) using poly(dT) 
primers and the manufacturer’s procedure. Negative controls during reverse transcription (RT) 
were created by replacing the enzyme mix with an equivalent volume of nuclease free water. 
Droplet Digital PCR (ddPCR). After synthesizing cDNA, ddPCR was performed using the 
QX200™ Droplet Digital™ PCR System (BioRad). This procedure partitions a single PCR 
reaction into 20,000 water-oil emulsion droplets to increase the fluorescence signal generated by 
a DNA target molecule by decreasing the volume of each individual “reaction” or droplet to one 
nanoliter. This then allows for low quantities on the level of 4 copies to be accurately measured 
to result in absolute copy information. 
  A volume of 2.2 µL of cDNA from reverse transcription reaction was mixed with 11 µL 
QX200™ ddPCR™ EvaGreen® Supermix (BioRad), 2.2 µL of combined forward and reverse 
primers at 125 nM (primer design seen in Table 7), and 6.6 µL of nuclease free water for a final 
volume of 22 µL to ensure accurate pipetting of 20 μL into the PCR.  
Reaction mixes were parsed into droplets using the instructions provided by the 
QX200™ Droplet Generator manufacturer (Bio-Rad), where the sample is randomly distributed 
based on a Poisson distribution so a single droplet either contains no template or one or more 
templates of DNA. The QX200™ Droplet Generator applies a vacuum to the wells filled with 
either oil or sample to draw the fluids into a flow-focusing junction and create monodisperse 
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droplets. The cDNA contained in the droplets was then amplified using a C1000 Touch™ 
Thermal Cycler with a 96-well Fast Reaction Module (Bio-Rad) under the following protocol: 
95° C for 5 min, 40 cycles of: 95° C for 30 s, 50° C for 30 s, and 72° C for 1 min, 4° C for 5 
min, and 90° C for 5 min. A final step of 4° C was used to cool the reaction mixture. After PCR 
amplification, the 96-well plate was placed in the QX200 droplet reader (Bio-Rad), with the 
fluorescence signals analyzed through QuantaSoft software (Bio-Rad). The resulting copy 
concentrations (copies/µL) were then normalized to the concentration of TRNA input into the 
reverse transcription reaction accounting for cDNA dilution factors when necessary. 
Table 7. Primer designs for ddPCR amplification of cDNA. 
Gene/cDNA Forward 5'-3' Reverse 5'-3' Product size (bp) 
EpCAM TTTTAAGAAATTCAGTTTAAAATGTT ACTGATTTGTGATTGAAAGC   104 
CRT19 CCCTTGGACCATAAATTTTTA CTTCTGCTGTCCTTTGG 108 
CD24 TTGCTCTTTCAGCCATT GTTTGTGTATTTACGCTTTG 96 
CD44 TCGAAGAAGTACAGATATTTATTAT ATTAAACCCTGGATCAGTC   107 
Vim TTTCCAAAGATTTATTGAAGC AATCTTGTGCTAGAATACTTT  112 
FAP v2 TAGCACTTGAACTTCTGA  AAGGGAGTCATGCATTT 87 
CD81 GGAGGGAACAAGGTGAG TGTAGGTGGCGTGTATG 210 
IL-8 AAGTTTCAACCAGCAAGAA TGATACTCCCAGTCTTGTC 131 
 
The software program uses the fraction of positive droplets, 𝑝, and the probability that a 
certain amount of copies will be present in a droplet determined by a Poisson distribution, 𝑝, to 
calculate the amount of copies per droplet of end product using the equation: 
𝑐𝑜𝑝𝑖𝑒𝑠 𝑝𝑒𝑟 𝑑𝑟𝑜𝑝𝑙𝑒𝑡 =  −ln (1 − 𝑝)  (Eq. 1) 
These primers were specifically designed to amplify sequences close to the mRNA’s poly(A) tail and span the 
length of two exons, reducing the risk of amplifying genomic DNA through the intron. The gene panel chosen 
includes epithelial genes (EpCAM, CRT19), mesenchymal genes (VIM, FAPv2), breast cancer stem cell markers 
(CD24, CD44), a common EV tetraspanin CD81, and angiogenic cytokine IL8. 
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With the number of droplets generated known through the detection of the Eva Green dye 
which only fluoresces if it attaches to double-stranded DNA (dsDNA) product. The absolute 
amount of target product can then be obtained, with the graph in Figure 21 applying a Poisson 
distribution based on the number of positive droplets to result in copies/µL. The dynamic range 
of the instrument according to the Bio-Rad QX200 ddPCR manual is from 4 to 100,000 total 
copies detected in the 20 µL reaction. 
 Copy results were then normalized back to the mass of total RNA (TRNA) input into the 
reverse transcription (RT) reaction (2 µL of TRNA), considering any dilutions made to the 
cDNA before adding to the ddPCR reaction as well as the dilution inherent of taking 2.2 µL of 















Fraction of positive droplets (out of 20,000)
ddPCR resulting copy concentrations are calculated by the software program by measuring the fraction of positive 
droplets through fluorescence detection of the product-annealed Eva Green dye. The software then applies Poisson 
statistics based on this fraction of positive droplets, as the cDNA target molecules are parsed into droplets based on 
a Poisson distribution. The fraction of positive droplets is calculated based on a maximum of 20,000 droplets 
produced by the QX200 Droplet ™ Generator (Bio-Rad). The dynamic range of the QX200™ Bio-Rad ddPCR is 
from 0.2 copies/µL to 5,000 copies/µL according to the manufacturer’s user manual. 
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 (Eq. 2) 
Any heat map plots were then either scaled based off of the highest normalized copy 
value found in a single heat map, or each individual column in the heatmap was scaled to the 
highest expressed gene resulting within the sample creating a ratio from 0 to 100%. 
2.2 Results and Discussion 
2.2.1 EV-MAP device fabrication and replication fidelity 
Future applications such as translation into commercialization or use in large clinical trials were 
considered when choosing a fabrication procedure for the EV-MAP device. The hot embossing 
of thermoplastic provided these capabilities by facilitating high throughput device manufacturing 
critical to any large-scale implementation. Further, the thermoplastic substrate is low cost and 
easy to handle making it an attractive material for such applications, and also working as a viable 
material for future industrial manufacturing through injection molding[196]. COC was chosen 
because it is known to create relatively higher uniform carboxylic acid coverage after UV/O3 
irradiation than other thermoplastic materials such as poly (methyl methacrylate) (PMMA), 
therefore facilitating high mAb surface load onto the EV-MAP device following UV/O3 
activation [195].  
To assess the fidelity provided through the fabrication procedure to the original device 
design (see Figure 18B), profilometry was performed on the mold master and replicated devices 
after hot embossing with a Keyence VK-X 3D laser scanning confocal microscope equipped 
with a 10X objective. Example images obtained for the mold master and embossed device are 
shown in Figures 22A, B. Pillar diameters, spacing (top and bottom), and pillar heights were 
measured for assessing accurate pattern transfer. The Keyence could not image through the cover 
plates or plastic bottom of the device after annealing because the microscope uses light scatter to 
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generate the topography of the surface. When light hits another medium such as a cover plate 
before reaching the structures, the path bends both on its way through and out of the device and 
would create an inaccurate profile of the geometry. Instead, devices were imaged at 9 locations 
after annealing the cover plate to the embossed device via a Nikon Optiphot 2 Trinocular 
microscope with a 10X objective (0.30 Ph1), Nikon 12V 100W Halogen Lamp, and 5MP 
USB3.0 Real-Time Live Video Microscope Digital Camera (AmScope) using the AmScope 3.7 
software (Figure 22A). Final images after annealing were analyzed using a custom macro 
(Appendix A3) created for ImageJ software to measure the interpillar spacing and pillar 
diameters. However, pillar height could not be assessed using this method.  
Each stage in the fabrication procedure showed high reproducibility from the mold to the 
final assembled device (Table 8). Only one spacing value could be measured using the images 
obtained from the Nikon microscope for annealed devices. Therefore, the top and bottom 
spacings were averaged together to determine an overall spacing from the mold and embossed 
devices. Both the pillar diameters and spacing showed no significant difference throughout the 
fabrication procedure (Table 8), with p >0.05 for 95% confidence between all data sets from a 
two-tailed t test. Hot embossing also had little effect on the pillar height; showing no significant 
difference with respect to the height measured from the mold master (p >0.05 for 95% 
confidence using two-tailed t test). Maintaining the designed architecture of the EV-MAP device 
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was critical for maximizing EV recovery determined through simulations which helped optimize 
these device dimensions (discussed below). 




Pillar spacing Pillar height 
Master mold 113.7 ± 1.5 23.2 ± 1.8  88.6 ± 1.4 
Before 
annealing 112.9 ± 1.5 23 ± 2.5 88.1 ± 3  
After 
annealing 
112.3 ± 1 22 ± 2 - 
(A) Representative images of master mold (left), embossed device before annealing (middle), and annealed device 
(right). Scale bar is 100 µm. (B) Example images of profilometry analysis performed through Multifile Analyzer 
software (Keyence), showing high reproducibility of dimensions between the mold and embossed device. 
Pillar height for annealed devices could not be measured because Keyence could not image over the coverslip or 
plastic bottom of the device due to the bending of the light scattering created by the surfaces. Therefore, only pillar 
diameter and spacing were analyzed using a custom ImageJ macro after procuring images from a Nikon Optiphot 2 
Trinocular microscope. Statistical comparison of all dimensions between each step showed no significant difference 
(p > 0.05 for 95% confidence using a two-tailed t test across all data sets). 





2.2.1 EV-MAP recovery simulation through Monte Carlo modeling 
The design of the EV-MAP was predicated on the diffusion of EVs to the microchannel walls 
populated with mAb. Collaborators in Dr. Soper’s group designed the EV-MAP device by 
testing various geometries and device architectures through simulations to model the diffusive 
transport of an EV when hydrodynamic Poiseuille flow, diffusional dynamics, and EV-mAb 
binding kinetics are applied to determine the optimum device dimensions for maximum EV 
recovery. While COMSOL can simulate both hydrodynamic and mAb binding physics, its 
estimation of EV recovery required modeling diffusion through the entire bed length of 122 mm, 
and with this large geometry it made the simulations numerically intractable. Therefore, Monte 
Carlo methods were used. 
Monte Carlo simulations model the probability of many different outcomes made 
possible due to the random nature of the variables involved. The simulations randomly selected 
variable values from a realistic input range to result in the most extreme or most conservative 
outcomes along with every possibility in between. Many trials were performed until the average 
results converged to a single outcome. This repeated random sampling and probabilistic view of 
end results make the Monte Carlo method well-suited for simulating systems with multiple 





The EV-MAP Monte Carlo model tracked the convective and diffusive motion of a single 
EV through a “straight” channel (corrected for the circular pillar geometry). The pressure-driven 
flow through a microchannel produces a Poiseuille flow characterized by a parabolic profile, 
Monte Carlo simulations were used to theoretically assess the recovery of EVs from different device architectures 
as well as flow rates. The recovery of EVs depends on two things: the diffusive transfer of an EV to an mAb-coated 
micropillar surface and the probability that that EV will successfully bind to the mAb at the surface. (A) Example 
EV-MAP Monte Carlo simulation. Each line within the microchannel is associated with the path of a single EV 
(not to scale), where red is associated with a high velocity (1.5 mm/s) and blue is a low velocity (0 mm/s). An “X” 
indicates successful EV-mAb binding while “O” denotes loss of the EV through the channel. In this simulation, the 
channel measured 10 µm in width, with each 100 nm EV moving at V
ave
 = 1 mm/s. The 100 nm EV has a diffusion 
coefficient of 5 µm/s
2
. The EVs traveled through an effective bed length of 35 mm, corrected for the circular pillar 
geometry (π/2). In this simulation, 14 EVs were successfully captured while 1 EV escaped through the channel 
corresponding to a 93% recovery. (B) Flow chart of the Monte Carlo model for EV-MAP. First, the simulation 
randomly sends an EV through the microchannel based on a Gaussian distribution to model diffusion dynamics and 
tracks their position. If an EV diffuses toward a micropillar surface, the mAb-binding kinetics determine if the EV 
will successfully bind. If not, the EV is continually moved through the channel. Acknowledgements to Dr. Matt 
Jackson of the Soper group. 
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Figure 23. Example of Monte Carlo EV recovery simulation and schematic of incorporated physical dynamics. 
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with EVs close to the wall experiencing a velocity close to 0 mm/s due to the no-slip condition 
generated by Poiseuille flow in a microchannel (Figure 23) while EVs in the midline of the 
channel experience a maximum velocity, or 1.5 Vave (1.5 mm/s in simulation shown in Figure 
23). Additionally, the probability of EV-mAb binding upon interaction with a modified surface is 
also incorporated into the EV-MAP Monte Carlo model as not every interaction of an EV with a 
channel wall will result in successful EV-mAb binding. EVs are either recovered (X in Figure 
23) or lost (O in Figure 23), with the results averaged over thousands of randomly moving EVs 
until converging to an average EV recovery. In the simulation shown in Figure 23, a 93% 
recovery was achieved through the successful capture of 14 out of 15 EVs. Figure 23 provides a 
flow chart of how the EV-MAP Monte Carlo simulates an EV through the microchannel, with 
the simulation first propagating EVs through the channel dependent upon both the convection 
and diffusion dynamics. Then, once an EV comes into contact with a mAb-decorated surface, 
mAb-binding kinetics are included in the simulation to assess whether the antigen and mAb will 
successfully complex and result in the isolation of an EV. 
Theory of diffusion dynamics in the Monte Carlo simulations. The dynamics employed in the 
Monte Carlo model originate from the driving forces affecting EV affinity-selection. Affinity-
selection dynamics depend on two events: (1) The delivery of the EV to the mAb-immobilized 
EV-MAP surface; and (2) successful binding of the mAb to the EV. Therefore, both the fluid 
dynamics and chemical physics were critical in designing the EV-MAP micropillar beds. The 
chemical physics incorporated in affinity-selection have previously been outlined for CTCs [98, 
200] as well as diffusional models for the affinity-selection of membrane proteins [201]. 
However, the diffusional model used for EV-MAP simulations includes some advancements. 
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The delivery of EVs to the mAb-immobilized EV-MAP surfaces depends on the ability 
of the EV to diffuse through the plasma matrix. Hydrodynamic pumping of the EV through the 
device causes it to diffuse laterally and longitudinally according to Fick’s Second Law of 
diffusion that is applied in non-steady state diffusional scenarios when the concentration of the 
diffusing species is a function of both time and position. Applying this law to EVs then states 
that for a small time increment, 𝛥𝑡, the probability that an EV will diffuse a distance 𝑥𝐷 from its 








2𝜎2  (Eq.3) 
The standard deviation of this Gaussian distribution is given by = √2𝐷𝛥𝑡 . In accordance with 
Fick’s second law, smaller EVs are more likely to diffuse farther over a certain time 𝛥𝑡 due to 
their higher diffusion coefficient (𝐷). 
The pressure driving the fluid through the device causes the EVs to experience Poiseuille 
flow. In an EV-MAP microchannel with a width of 𝑊, an EV’s forward velocity at a position 𝑥 
from the middle of the channel is approximated by: 





  (Eq. 4) 
The average velocity (𝑉𝑎𝑣𝑒) is calculated by dividing the volumetric flow rate by the bed’s cross-
section. This parabolic flow profile creates a dependence on the time available for EV diffusion 
based on the lateral position of the EV within the channel. When an EV travels closer to a device 
surface, the EV forward motion slows due to the no-slip condition experienced near a 
microchannel wall, allowing more time for diffusion to occur. Therefore, if one EV takes a 
random path leading closer to the surface, it will experience a different residence time than 
another EV following a separate path. This variability affects EV recovery based on differing EV 
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paths and thus required many simulations of individual EVs moving in random trajectories until 
the results converged to an average. Incorporating the diffusive probability and Poiseuille flow-
based theoretical particle velocity into the Monte Carlo model allowed testing of various bed 
lengths (𝐿), inter-pillar spacing (𝑊), and average flow velocities (𝑉𝑎𝑣𝑒) to optimize the design of 
EV-MAP for high recovery, high throughput, and high surface area to maximize EV load.  
The Monte Carlo model simulated EV diffusion by changing the lateral position (𝑋 
dimension) and longitudinal position (𝑌 dimension) over finite time steps (𝛥𝑡) as shown: 
𝑥(𝑡) = 𝑥(𝑡 − 𝛥𝑡) + 𝑟𝑎𝑛𝑑(𝑃(𝜎(𝐷, 𝛥𝑡))  (Eq. 5a) 
𝑦(𝑡) = 𝑦(𝑡 − 𝛥𝑡) + 𝑉(𝑥(𝑡 − 𝛥𝑡)) + 𝑟𝑎𝑛𝑑(𝑃(𝜎(𝐷, 𝛥𝑡))  (Eq. 5b)  
The EV’s lateral 𝑥 position changed with lateral diffusion over 𝛥𝑡 by 𝑟𝑎𝑛𝑑(𝑃(𝜎(𝐷, 𝛥𝑡)), which 
is determined through a pseudo-random number generator that propagates the EV laterally based 
on a Gaussian 𝑃(𝑥) distribution with standard deviation 𝜎 due to Fick’s law. The longitudinal 
motion is simulated in the same manner with the additional effect of Poiseuille flow included 
through the 𝑉(𝑥(𝑡 − 𝛥𝑡)) term.  
mAb-binding dynamics in Monte Carlo simulations of EV-MAP recovery. Though the 
Monte Carlo model implementing both hydrodynamic flow and diffusion dynamics may 
simulate an EV interacting with an EV-MAP mAb-coated surface, it is not guaranteed the EV 
will successfully bind to the mAb. Often, multiple encounters are necessary to recover a single 
EV. To incorporate mAb-binding dynamics into the simulation, the Chang-Hammer model [202] 
was applied to describe the likelihood of surface-confined mAbs binding to passing antigens 
found on an EV membrane. The model approximated the amount of EVs that will bind to the 
surface by including: (1) mAb-antigen binding kinetics; (2) the motion of the antigen (in this 
case EV) and the associated residence time in proximity to the surface-restricted mAb; and (3) 
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the rolling distance of the EV along the surface. The Chang-Hammer model has been previously 
simplified [200]. 
 When considering the rolling distance of the EV, the forward rate constant 𝑘𝑜 defining 
the encounter of antigens with a surface-confined mAb is written as: 
𝑘𝑜 = 2𝑎𝑖𝑉𝑒𝑓𝑓  (Eq. 6) 
The mAb-antigen interaction radius is 2 nm (𝑎𝑖) in this case[203]. 𝑉𝑒𝑓𝑓 refers to the velocity of 
the antigen relative to the surface, resulting in 0.47 times the rolling EV’s velocity due to the 
opposing rotational motion of the EV surface continuing to traverse the EV forward. When an 
antigen encounters a surface-confined mAb, the probability that they will complex (𝑃) depends 




  (Eq. 7) 
𝑘𝑖𝑛 is based on the Ab’s specific kinetics and thereby treated as a constant not affected by the 
motion of the antigen. However, the duration of the interaction is dependent upon the interaction 
radius and effective velocity. An increase in EV linear velocity causes the encounter duration to 
decrease creating less time for the mAb and antigen to complex and consequently reducing 
binding probability. Therefore, the antigen’s forward rate constant (𝑘𝑜) and the binding 
probability (𝑃) are inversely related to one another in yielding an effective forward rate constant, 
𝑘𝑓 is: 
𝑘𝑓 = 𝑘𝑜𝑃  (Eq. 8) 
This 𝑘𝑓 represents the probability that the reaction will occur. Lastly, because EV-MAP is 
concerned with adhesion of an EV, which could harbor one or several surface antigens, both the 
forward rate constant,𝑘𝑓, and the antigen surface density 𝐶∞ determine the overall adhesion rate 
constant (𝑘𝑎𝑑) of the EV to the surface: 
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𝑘𝑎𝑑 = 𝑘𝑓𝐶∞  (Eq. 9) 
In summary, 𝑘𝑎𝑑 accounts for the EV’s antigen expression and velocity of those antigens, based 
on how often the antigens encounter mAbs and how likely a binding event is given the duration 
of antigen-mAb interaction and the mAb’s binding kinetics. This resulting rate of EV adhesion 
relates to an experimental system when considering an EV moving along a mAb-coated surface 
at a linear velocity (𝑉) for some distance (𝐿). In this relevant scenario, the percent of EVs that 
will bind is determined through: 
%𝑏𝑜𝑢𝑛𝑑 = 1 − 1/𝑒
𝑘𝑎𝑑𝐿
𝑉   (Eq. 10) 
It is apparent from Eq. 10 that minimizing the linear velocity and maximizing the length 
at which the EV interacts with the surface will improve EV recovery. EVs have a high diffusion 
coefficient due to their relatively small size, with the dynamics of an EV rolling along a 
micropillar surface described by a Peclet number <1 due to the negligible convection 
experienced at the channel side walls because of the no-slip condition in Poiseuille flow. The 
motion of the EV at this location is therefore almost entirely dependent on the diffusion, which is 
challenging to externally control as it is a random process. Therefore, manipulating the lateral 
diffusion and length of EV-micropillar interaction proves challenging. Furthermore, because of 
the no-slip condition limiting the surface flow velocities to approximately zero, decreasing the 
bulk flow rate or flow velocity will provide little effect to the linear velocity in Eq. 10. Based on 
these limitations, it is most practical to manipulate the chances with which the EV has to interact 
with the surface than to manipulate each moment of interaction. Therefore, decreasing inter-
pillar spacing or increasing bed length would allow for more time and shorter diffusional 
distances to maximize the amount of interactions a single EV could have with the Ab-coated 
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surface in hopes that one interaction would create a probability high enough to result in 
successful binding.  
Implementation of physical dynamics into Monte Carlo model. The fluid dynamics explained 
above were incorporated into Monte Carlo simulations for modeling EV recovery. The curving 
flow path along a bed with length 𝐿𝑏𝑒𝑑 was approximated as a straight microchannel with a 
width 𝑊 equal to the interpillar spacing and length 𝐿 =  𝐿𝑏𝑒𝑑𝐶. 𝐶 is a correction factor to 
elongate the flow path due to the pillar’s circular geometry when constraining it to a straight 
channel, (𝐶 = 𝜋/2  ≈ 1.57) [201]. EVs started at 11 possible positions at the beginning of the 
pseudo-channel, and their positions through the channel were propagated by Eqs. 5. If an EV 
encountered the channel surface (𝑥 = ±𝑊/2), the EV moved forward a certain distance dictated 
by multiplying the EV’s forward velocity 𝑉(𝑥) (Eq.4) with the simulation’s time step ∆𝑡. This 
rolling distance was then used to calculate the probability of binding from Eqs. 6-10, with this 
probability turned into an actionable decision (either bound or not bound) by using a pseudo-
random number generator under a uniform distribution between 0 and 1. If the random number 
proved less than or equal to Eq. 10’s binding probability, the EV was captured on the device. For 
example, if the interaction event correlated to a 10% binding probability, then 10% of the pseudo 
random numbers could result in successful complexing making any number less than or equal to 
0.1 count as a successful binding event. If this did not occur, the EV was further moved through 
the channel via Eqs. 5. 
 Each EV’s path was considered a binary event as either recovered or lost, with thousands 
of EVs tracked until the simulated recovery converged. This convergence was met only if: (1) A 
<0.01% change in the average recovery was observed when additional EVs were tracked through 
a single simulation; (2) a <10% standard deviation occurred for five repetitive simulations run 
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under the same channel architecture; and (3) a difference of <1% was observed from the average 
solution of five simulations after halving the ∆𝑡 increment, otherwise the simulations would be 
repeated after halving ∆𝑡 again (Figure 24). The decreasing of time steps was important to track 
the EV realistically through slight differences in particle path caused by Brownian motion. As 
can be seen from Figure 24, a large time step drastically effects recovery results with an 80% 
recovery achieved by 2 ms between EV motion tracks vs. a <60% recovery resulting from a 0.16 
ms time step. Furthermore, the more variable distribution observed with less EVs tracked 
through the channel highlights the need for more EVs to be simulated in order to create highly 
reproducible EV recoveries for fixed microchannel conditions. 
EVs are continuously sent through the microchannel in a single simulation, with the addition of more EVs only 
stopping once the average recovery converges to <0.01% difference than the average recovery resulting before the 
addition of another EV(*). After converging based on the number of EVs, a time step convergence criterion is 
applied where ∆𝑡 is halved until the averaged recovery of five simulations converges to <1% error change (**), 
with these simulations run under the same channel geometry and flow conditions. This criterion was important in 
accurately tracking small position changes of the EV caused by Brownian motion. A third convergence criterion 
which is not shown above required the standard deviation of five sequential simulations performed with the same 
parameters and conditions to be <10%. The results shown were simulated for a 100 nm EV with diffusion 
coefficient, D = 5 μm2/s, starting in the center of the channel, with effective bed length accounting for circular 
pillar geometry L = 35 mm and W = 10 μm, and infused at an average velocity of 1 mm/s. Acknowledgements to 
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* dt = 2 ms
Figure 24. Example showing convergence of simulations to an average EV recovery. 
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The dynamics applied in the EV-MAP Monte Carlo simulations were validated through 
subsequent addition of various forces affecting EV-Ab binding. Initially, all recovery effects 
were removed and EVs allowed to move freely in solution only propagated through random 
Brownian motion with no wall constraints. In this scenario, Fick’s Second Law (Eq. 1) is valid 
and the results from the Monte Carlo simulation match well with a Gaussian distribution 
produced from Eq. 3 (Figure 25). Wall constraints were then introduced into the model along 
with convective flow driven hydrodynamically, only negating the mAb-binding dynamics so that 
any surface interaction led to EV recovery. In this simulation, 64% of EVs were recovered 
showing a high variability in spatial distribution even when only considering the lateral direction 
(represented by blue bars in Figure 25). This is because Fick’s law is rendered invalid when the 
EV concentration is no longer constant due to the addition of favorable EV-affinity selection to 
the channel surfaces (represented by -W/2 and W/2 in Figure 25). All subsequent simulations 
used EV sizes, diffusional coefficients, and surface densities found in Table 9 for estimating EV-





The Ab-binding Chang-Hammer dynamics (with parameters used for Monte Carlo 
simulations shown in Table 9) were then applied to the Monte Carlo simulation to include a 
probability with every EV that came into contact with a mAb producing a substantially lower 
recovery (16%) for a simulated small 10 µm inter-pillar spacing but short effective bed length of 
4 mm (taking into account the correction factor for circular pillar geometry) and average velocity 
of 1 mm/s. The shorter bed length decreased the overall time available for lateral diffusion 
EVs were diffused laterally amidst Poiseuille flow, with the lateral position tracked based on the channel’s width 
(W). The x axis of the graph correlates to the lateral position of an EV when reaching the end of the channel. The y 
axis then shows the probability that EVs from the simulation will end in these lateral positions, with -W/2 and W/2 
referring to the walls of the channel and therefore showing the recovered EVs. Simulations disregarding affinity-
binding dynamics, wall constraints, and Poiseuille flow thereby only considering an EV’s natural diffusion path 
(grey bars) agreed with the analytical solution to Fick’s Second Law (hashed bars). However, when constraints of 
the microchannel and Poiseuille flow were applied (blue bars), the EV spatial distribution is no longer Gaussian. 
These conditions allow for the affinity capture of EVs to the channel walls, creating the large increase of EVs 
positions at -W/2 and W/2. The spatial distribution even changes drastically within the channel’s width. This is due 
to the invalidity of Fick’s law as EV concentration fluctuates. These results were computed for a D = 5 μm2/s, 
effective length (incorporating circular correction factor) L = 4 mm, W = 10 μm, Vave = 1 mm/s. Chang-Hammer 
dynamics were not applied, making all EV-mAb interactions successful. Acknowledgements to Dr. Matt Jackson of 
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Figure 25. Validation of Monte Carlo model with sequential addition of physical dynamics principles. 
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therefore contributing to the low recovery. This significant decrease in recovery highlights the 
importance of including mAb-binding probability in the EV-MAP model, otherwise 
unrealistically high recoveries could result due to the incorrect assumption that all mAb-EV 
interaction events end in successful EV binding. 
Table 9. Parameters used for Chang-Hammer dynamics (Eqs. 6-10) in Monte Carlo three bed EV-MAP simulations. 
Property Value Reference 
EV diameter 100 nm - 
Viscosity 8.9 x 10-4 Pa·s - 
Diffusion coefficient (D)  5 µm2/s - 
Minimum EpCAM surface density (C∞) 12.31 µm-2 [204] 
Anti-EpCAM binding kinetics (kin) 2.5 M-1s-1 [205] 
Ab-antigen encounter radius (ai) 2 nm [202, 203] 
 
After validating the model, EV-MAP recoveries under various inter-pillar spacings and 
volumetric flow rates (Figure 26) were assessed to determine the optimum device architecture 
and experimental conditions. 80% recovery was observed at a flow rate of 2.1 µL/min, with this 
high recovery being the reason it was chosen as the infusion flow rate for the samples used in 
this study as well as the practicality of allowing the sample processing to be performed in a 
single day. Interestingly, the simulated recoveries at various flow rates did not depend on the 
inter-pillar spacing because increased diffusional distances were counteracted by decreased 
linear velocities to create a constant flow rate. This was important as the fabricated devices had a 





Evaluation of Shear stresses in EV-MAP devices. It was important to investigate the shear 
stresses placed upon EVs within the EV-MAP device to ensure the biological particles would not 
be lysed or damaged, as well the shear forces not release the EVs from the surface to which they 
were bound. COMSOL Multiphysics simulations derived the shear stress profiles (Figure 27) 
from the parameters outlined in Table 10, with results showing a shear stress of 3.1 dynes/cm2 at 
the pillar walls under the highest linear velocity of 3.7 mm/s, with this shear stress proving much 
lower than the adhesion force of an EV to the surface which amounts to 150,000 dynes/cm2 (See 
Section 2.2.2) thereby ensuring the flow rate alone would not shear EVs from the surface. 
Various interpillar spacings  (10,15, and 20 μm) and volumetric flow rates were tested through the Monte Carlo 
model to optimize the device design by maximizing recovery. All simulations were run using the full bed length of 
122 mm, corrected for the circular geometry of the micropillars (π/2). 100 nm EVs with a diffusion coefficient of 5 
µm/s2 traveled through the device. Acknowledgements to Dr. Joshua Matt Jackson of the Soper research group. 































Table 10. Parameters for COMSOL simulations of laminar flow dynamics to assess EV-MAP shear stresses. 
Parameter Value 
Physics Laminar flow, 
stationary 
Viscosity 0.0345 Pa s 
Density 1.055 g/mL 
Inlet 2.1 µL/min (0.21 
mm/s) 
Outlet 0 Pa 
Pillar height 90 µm 
Pillar diameter 110-120 µm 
Inter-pillar spacing 10-20 µm 
Draft angle 4.6° 
Program COMSOL 5.2a 
Number of elements 11,528,872 
Average element quality 0.6754 
Solver GMRES 
Tolerance 10-3 
3-dimensional laminar flow dynamics were applied to the EV-MAP prototype to simulate shear stresses imparted on 
the EVs in a microfluidic channel. The parameters for geometry were empirically derived through confocal, laser-
scanning profilometry measurements of the EV-MAP device. 
3-dimensional velocity cross-section and shear stress profiles between two adjacent micropillars resulting from 
COMSOL Multiphysics simulations. Symmetry constraints were employed along two sides of the simulation to 
achieve high element quality by reducing the number of elements required (Table 10) to decrease computational 
















Figure 27. Evaluation of Shear stress applied between two micropillars. 
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2.2.2 Depletion of EVs from FBS in culture media: Depletion efficiency and protein 
analysis. 
FBS-derived EVs create significant background to overcome when analyzing cell-specific EVs 
shed in culture media. To decrease this background signal, ultracentrifugation at 100,000g 
removed bovine-derived EVs from FBS [206]. A single ultracentrifugation step for 6 h pelleted 
EVs from 60 mL of stock FBS, with two sequential ultracentrifugation passes of 3 h performed 
on the respective supernatants to detect and quantify any remaining EVs after initial depletion. 
The TRNA size profile and concentrations from the residual EV pellets were then compared to 
the TRNA extracted from the pellet after initial 6 h ultracentrifugation of the stock FBS to 
determine depletion efficiency. All TRNA fractions maintained similar size distributions ranging 
from 200 – 4000 nt as visible through HS RNA Tape (Figure 28A), with the depletion of EVs 
visualized through TEM images after 6 h ultracentrifugation on the supernatant ( designated by 
black arrow in Figure 28B). The TRNA extracted decreased from 390 ng in 60 mL of stock FBS 
to 17 ng per 60 mL in EV-depleted stock FBS (Table 11). A 96% depletion efficiency was 
achieved after 6 h of ultracentrifugation. 
For the duration of this study, all cell lines were cultured with diluted 10% EV-depleted 
FBS creating a background of 2.8 pg TRNA/mL of media. These depletion results coincided well 
with the literature [206]. However, when employing extended ultracentrifugation (18-22 h, 
100,000g) for EV depletion, a sedimentation gradient of proteins was observed. Additional 
depletion of proteins along with EVs could decrease the growth of cells within the culture media. 
Therefore, the protein gradient was analyzed for total protein content through protein 
quantification of 10 mL fractions from the 60 mL of FBS after ultracentrifugation using the 
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EZQ™ Protein Quantification Kit (Invitrogen). The protein size distribution in each fraction was 
also assessed using a non-reducing SDS-PAGE with Coomassie R250 staining. 
 
Table 11. TRNA yield from ultracentrifuged stock FBS and the residual EVs. 
TRNA source ng TRNA per 60 mL TRNA size range 
FBS EVs (6 h, 100,000 g) 390.1 ±14.1 <2,000 nt 
Residual FBS EVs (3h, 100,000 g) 17.7 ±3.9 <2,000 nt 
Residual FBS EVs (6h, 100,000 g) 16.8 ±1.5 <2,000 nt 
Stock FBS was ultracentrifuged at 100,000g for 6 h (yellow lines) with the resulting pellet lysed for TRNA 
extraction. The supernatant or EV-depleted FBS was then sequentially ultracentrifuged for two 3 h steps, with the 
TRNA extracted from the pellet after 3 h (grey lines) and 6 h (black lines). All procedures were run in duplicate. (A) 
TRNA size distribution and relative abundance. TRNA was analyzed using HS RNA tape, with the marker band 
denoted at 25 nt. Residual EV TRNA was still present in undiluted FBS after 3 h and 6 h of ultracentrifugation. (B) 
TEM images of EVs from the initial 6 h ultracentrifugation performed on stock FBS and residual EVs remaining in 

















































1000 FBS EVs 
3 h depletion 
6 h depletion 
A B 
Figure 28. TRNA size distribution and TEM images of residual EVs after 6 h ultracentrifugation of FBS. 
 TRNA mass resulting from the samples shown in Figure 28, with 60 mL of stock FBS and subsequent EV-depleted 
supernatants after 3 and 6 h ultracentrifugation steps analyzed. TRNA concentration was measured using the HS 
RNA Tape, then multiplied by the total TRNA elution volume to result in ng of TRNA from 60 mL FBS. The mass 




For protein size characterization, the samples were loaded into the 10% polyacrylamide 
gel (Mini-PROTEAN® TGX™ Precast Protein Gel, Bio-Rad) with Laemmli buffer (Bio-Rad), 
heated to 95 ° C for 5 min, then run through the gel at 200 V in Tris/Glycine/SDS buffer (Bio-
Rad). The gels were prefixed with 10% acetic acid for 30 min, stained with 3 g/L Coomassie 
R250 in 10% acetic acid for 1 h, with the stain removed in 7.5% acetic acid (4 h in orbital 
shaker). Images of the gel were taken with a Kodak Gel Logic 200 system. 5 µg bovine serum 
albumin (BSA) was used as a protein sizing control in the gels.  
  
Protein content analyzed from 10 mL fractions of 60 mL of stock FBS after extended ultracentrifugation for 22 h at 
100,000g showed a gradient of proteins (top left picture) suggesting higher density proteins may sediment toward 
the bottom of the flask. Protein was quantified using the EZQ™ quantification kit (Invitrogen) which uses protein 
blotting onto a paper support and measures fluorescence intensity to compare unknown samples to a standard 
calibration curve of ovalbumin. Protein content of both the 100% stock FBS and final EV-depleted FBS after mixing 
and decanting the supernatant are also shown in the graph to highlight the preservation of most proteins through this 
























































































Figure 29. Analysis of protein content after extended (22 h) ultracentrifugation of stock FBS 
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Analysis of the protein content showed an increased protein concentration closer to the 
bottom of the centrifugation tube (Figure 29) or in the 60 mL fraction. Through both SDS-
PAGE (Figure 30) and protein content analysis it was proven that indeed proteins sedimented 
into the pellet after prolonged ultracentrifugation, with these proteins having high molecular 
weights (Figure 30). However, decanting and mixing of the supernatant after ultracentrifugation 
preserved 91% of the total protein content found in the FBS stock (Figure 29) and maintained 
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The fractions from Figure 29 were also analyzed through SDS-PAGE with Coomassie R250 staining to assess 
the size distribution of proteins found in all fractions of the ultracentrifuged 60 mL stock FBS. The red box 
outlines an increasing concentration of higher molecular weight proteins toward the bottom of the flask (in 
fractions 30-60, respectively) while the green box shows the preservation of these higher molecular weight 
proteins through mixing and decanting the supernatant after 18-22 h of ultracentrifugation. When the gel was 
run under non-reducing conditions, the band differed from the known molecular weight of BSA. Therefore, the 
samples and control were reduced with 5% 2-mercaptoethanol (Bio-Rad) before running on a second gel. This 
gel showed the BSA control with appropriate protein sizing and is provided here under the original gel. 
 
Figure 30. Fractional analysis of protein sizes after extended (18-22 h) ultracentrifugation of stock FBS. 
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step was included in EV-depletion of FBS for cell culture using an 18 h ultracentrifugation step 
to maintain the required protein content for optimum cell growth. 
2.2.4 Effects of differential ultracentrifugation on the heterogeneity of EV populations. 
Differential ultracentrifugation serves as the gold standard for EV isolation, though limitations 
are associated with the procedure [207, 208]. Differential ultracentrifugation often results in 
lower EV yields due to loss of EVs either through premature sedimentation from EV aggregation 
or EVs remaining in the supernatant [209-211]. To investigate the EV populations recovered 
through differential ultracentrifugation as well as potential loss of EVs, EVs were harvested from 
60 mL of MCF7 and Hs578T breast cancer cell media conditioned in 10% EV-depleted FBS 
through the differential ultracentrifugation protocol outlined in Théry et al. [149] (protocol also 
outlined in the Benchtop isolation section of Chapter 2. Introduction): 300g and 2,000g to 
remove cells, debris; and apoptotic bodies 10,000g to deplete vesicles >150 nm; and 100,000g 
for pelleting the remaining EVs, then washing with PBS (pH = 7.2). Pellets formed after 10,000g 
centrifugation and 100,000g ultracentrifugation were lysed with the TRNA extracted, purified, 
and subsequently analyzed using HS RNA Tape (Agilent Technologies).  
The TRNA size distribution (between 200-1000 nt with a majority of TRNA between 
200-500 nt, Figure 31) was consistent with TRNA sizes often found in EVs [133]. Three to four 
µg of TRNA was isolated from 106 cells to compare the contrasting cellular TRNA profile 
showing high abundance of 28S/18S rRNA visible (Figure 31) to the absence of such rRNA in 
the EV TRNA fraction. TRNA was observed in the 10,000g fractions (~60 pg/mL of medium) 
(Table 11), suggesting the loss of larger EVs such as microvesicles to this initial 10,000g step. 
However, this TRNA concentration is small in comparison to the TRNA yield from EVs pelleted 
87 
 
at 100,000g, collecting 880 pg/mL MCF7 media and 545 pg/mL Hs578T media, respectively 
(Table 11).  
 
Table 12. TRNA concentrations from cell line EV pellets collected during differential ultracentrifugation. 
TRNA source Spin speed  
(×g) 
pg TRNA  
per mL 
Blank media  100,000 28.3 ±3.33 
MCF-7 
10,000 58.3 ±25 
100,000 880 ±31.7 
Hs578T 
10,000 60 ±28.3 
100,000 545 
MCF-7 lysate 106 cells 66,667 
Hs578T lysate 106 cells 61,667 
TRNA size distribution of EVs isolated from 60 mL of MCF7 or Hs578T conditioned media through differential 
ultracentrifugation (protocol outlined in Théry et al. [145] and discussed above in the text). EV pellets after 10,000g 
and 100,000g steps were lysed for EV TRNA, with TRNA extracted and the trace shown from cells for comparison. 
The EV TRNA showed no 18s or 28s peaks as opposed to the 18s and 28s peaks clearly visible in the cell TRNA . 
Further, the FBS EV TRNA trace from ultracentrifugation showed a much higher level of TRNA compared to the 
conditioned media EVs. RNA was assessed using HS RNA Tape. The peak at 25 nt represents the marker band. 
10,000g pellets are shown by the light-weight lines toward the bottom of the graph, correlating to little TRNA 
content compared to the 100,000g fractions. 
TRNA concentrations for the samples shown in Figure 31. The blank media correlates to the FBS EV fraction 
above, showing the background TRNA content.  
Figure 31. TRNA sizing and abundance from EV pellets collected during differential ultracentrifugation. 
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TEM images were taken of the 100,000g pelleted fractions to qualitatively characterize 
the EV subpopulations isolated (Figure 32), by observing the morphology and manually 
measuring the diameter of each EV observed in the images to discern the relative size 
distribution for both the 100,000g pellets and the corresponding supernatants. A similar EV size 
range for MCF7 (25-83 nm) and Hs578T (20-80 nm) EVs was observed. However, the median 
size for MCF7 EVs shifted slightly higher to 51 nm vs. 37 nm for Hs578T. Analysis of the 
ultracentrifugation supernatant after 100,000g pelleting showed the presence of EVs <30 nm that 
were not isolated by ultracentrifugation (Figure 32, white bars), suggesting that a subpopulation 
of smaller EVs were lost during the ultracentrifugation step. 
These EVs may remain in the supernatant due to a difference in density causing them to 
sediment slower than other higher density EVs. An EV’s density depends on their cargo which 
varies greatly among each individual EV based on the cell of origin. This loss of EVs to the 
supernatant has been proven before by a group who performed western blotting on the 
supernatant incurred after differential ultracentrifugation to analyze the presence of EVs. They 
found 40% of total vesicular proteins detected through EV markers to reside in the supernatant, 
even after 200,000g ultracentrifugation [209]. Overall, both microvesicles and even small 
exosomes were found to be lost during differential ultracentrifugation, highlighting a need for 





2.2.5 EV-MAP assay optimization 
Proteolytic digestion for release of EVs from EV-MAP surfaces. NTA and TEM are two of 
the most common analytical tools used for quantifying EVs and qualitatively verifying their 
presence based on morphology, respectively. Methods for releasing EVs from microfluidic 
devices for downstream processing must not damage the EVs while also providing efficient 
cleavage of bonds holding the EVs to the surface. Due to the small size of EVs and high strength 
of the mAb-antigen bonds as well as the covalent attachment of the mAb to the microfluidic 
surface, manipulation of fluid shear forces cannot effectively remove EVs from the surface [95]. 
A single mAb-antigen bond (1.2 x 10-5 dynes [212]) securing a 100 nm EV would require 
150,000 dynes/cm2 for physical removal from the surface. As shown previously through the 
shear stress COMSOL simulations (see Figure 27), a flow velocity of 2.1 μL/min only delivers 
3.1 dynes/cm2 to the pillar surface. Therefore, chemically disrupting the mAb-antigen complex or 
TEM imaging of EV fractions from MCF7 and Hs578T conditioned media after differential ultracentrifugation 
(protocol described above in the text) and resuspension of EV pellet in PBS. The size distribution was determined 
through manual measurements of the EVs found in several TEM images, with example TEM images shown. White 
bars show the size distribution of EVs still present in the supernatant after differential ultracentrifugation as the 
supernatant was also subjected to TEM imaging. Scale bars set at 100 nm. 
 

































Figure 32. Size of cell line EVs from 100,000g pellets and supernatants after differential ultracentrifugation. 
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degrading the bond attaching the mAb to the surface of the microfluidic served as the most 
practical approach for EV release after affinity selection.  
One common strategy for Ab-antigen cleavage utilizes a proteolytic enzyme to digest the 
bonds forming the complex. Trypsin is a common proteolytic enzyme that has shown high 
efficiency for releasing CTCs from mAb-modified microfluidic devices [95]. Though it has been 
used frequently in CTC microfluidic removal, trypsin has yet to be applied for mAb-antigen 
digestion of EVs. Trypsin only digests lysine and arginine residues, proving sufficient for CTCs 
ranging in size from 12-25 μm [95], as the fluid force within the microfluidic aids in the cell 
removal negating the need for every Ab bond to be cleaved. However, with EVs ranging from 10 
to 400 times smaller in size, complete digestion of all residues binding the Ab to the antigen is 
critical.  
Proteinase K has been employed for efficient digestion due to its more stringent cleavage 
of all types of peptide bonds [162, 213]. The use of this stringent enzyme is predicated on the 
enhanced stability of EVs and their resistance to protease digestion. However, it is important to 
note that any use of a proteolytic enzyme will concurrently digest membrane proteins, which 
may be of interest to analyze in certain downstream applications such as EV protein 
quantification. Herein, the integrity of EVs was assessed after proteolytic digestion and an 




EVs were harvested from the breast cancer cell line SKBR3 through differential  
ultracentrifugation. The SKBR3 EVs were digested with 0.2% w/v proteinase K (from 100 
mg/mL dissolved in 50% glycerol with PBS) at 37 °C for 30 min followed by 10 min of 
sonication. Three conditions were tested: (1) EVs with no treatment (PBS control); (2) proteinase 
K digestion; and (3) a combination of proteinase K treatment with sonication. The samples were 
taken for NTA to discern any concentration or sizing differences observed between the samples 
(A) Concentration and (B) size distribution results from NTA data for SKBR3 EVs harvested by differential 
ultracentrifugation then subjected to either 30 min 0.2% proteinase K digestion alone or a combination of 0.2% 
proteinase K digestion and 10 min sonication. A sample of EVs was left untreated as a control to investigate the 
effects of the release procedure on the integrity of EVs. Error bars represent 5 separate NTA measurements of a 
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Figure 33. Investigation of SKBR3 EV integrity after proteolytic release and sonication. 
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(Figure 33A, B). No condition resulted in any significant change from the control (p = 0.5367 
and p = 0.0705 from an unpaired, two-tailed t test) when comparing to proteinase K treatment 
with or without sonication, respectively. The two proteinase K treatment samples showed a 
widening in EV size distribution (Figure 33B), ranging from ~100 – 500 nm as opposed to the 
shorter 100 – 250 nm range observed in the PBS control. However, the average size still 
converges around 200 – 250 nm regardless of the presence of proteinase K treatment. 
Furthermore, the proteinase K treatment or sonication does not seem to cause EV shrinkage 
because the size range does not expand toward the lower end of the spectrum. Overall, the 
proteinase K proved to maintain EV integrity by not lysing EVs shown by no drastic decrease in 
the concentration achieved. The treatment also showed little difference in the structure of EVs, 
still maintaining the same ~ 250 nm average. Proteinase K therefore may be used for release of 
EVs from surface capture reagents while keeping their membranes intact. 
To determine the efficiency of the proteinase K treatment, EVs were released from EV-
MAP devices (n = 12) through sequential steps after infusing 500 µL donor plasma. The first 
step comprised of a PBS control that was subjected to 30 min incubation at 37°C. The samples 
were then proteolytically digested using 0.05% trypsin in 0.53 mM EDTA. Trypsin was included 
as a well-established release method for mAb-antigen cleavage of biological particles. Next, 
proteinase K was used to digest mAb-antigen complexes at a concentration of 0.2% w/v in 
glycerol and PBS. A second proteinase K step released any remaining EVs to provide a reference 
point for efficiency calculations. All steps included 10 min sonication after identical incubation 
times and temperatures, with EVs released in PBS for NTA (Figure 34A). To determine the 
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release efficiency, EV aliquots were referenced to the steps both before and after through the 
following equation: 
𝐸𝑉𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑖𝑛 𝑠𝑡𝑒𝑝
𝐸𝑉𝑠 𝑜𝑛 𝑐ℎ𝑖𝑝
=
𝐸𝑉𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑖𝑛 𝑠𝑡𝑒𝑝
𝐸𝑉𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑖𝑛 𝑠𝑡𝑒𝑝+𝑠𝑢𝑏𝑠𝑒𝑞𝑢𝑒𝑛𝑡 𝑠𝑡𝑒𝑝𝑠
 (Eq. 10)  
(A) NTA concentration results of nanoparticles (NPs) released off-chip after sequential steps (shown blue, N = 12) 
using PBS, 0.5% trypsin with 0.53 mM EDTA, 0.2% proteinase K in PBS, and a second proteinase K digestion to 
serve as a final reference step for measuring release efficiency. A 10 min sonication step followed every sequential 
proteolytic digestion by 30 min incubation at 37 °C, including the initial PBS control incubation. The red lines 
represent NTA measured NPs released using a single proteinase K digestion step followed by a second proteinase K 
digestion as a reference for release efficiency (N = 4). (B) Box plots showing release efficiency based on the NP 
data shown in (A) and calculated using Eq. 10. A release efficiency of 99 ± 1% was achieved from a single 
proteinase K digestion (30 min, 37 °C) followed by 10 min sonication (dark navy blue box). 
Figure 34. Release efficiency determined by NTA concentration after sequential steps of proteolytic digestion. 
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 Few EVs were released from the initial PBS control; an average of 49% of EVs were 
released by subsequent trypsin digestion (Figure 34B) with an associated high variation between 
the samples (±27%). For proteinase K, 96% of EVs were released. To ensure proteinase K 
digestion on its own could produce the same high release efficiency, 4 samples were processed 
with a single proteinase K digestion step followed by a secondary proteinase K treatment to 
serve as a reference point for calculating release efficiency. The release efficiency associated 
with proteinase K digestion was highly reproducible at a resultant 99 ±1% (n = 4) from a single 
step (Figure 34B). The lower release efficiency observed through trypsin digestion could be 
attributed to the digestive selectivity of the proteolytic enzyme and not effectively cleaving all 
potential mAb-antigen associations.  
The high efficiency observed for proteinase K digestion is impressive due to the high 
strength of the affinity complex confining the EVs to the surfaces. Because extremely high 
forces are required to break even one bond, this data suggests that proteinase K can cleave all 
mAb-antigen bonds even at a relatively low concentration. Proteinase K digestion with a 
subsequent sonication step was found to efficiently release EVs from the EV-MAP surfaces (99 
± 1%) and maintain the integrity of the EVs for NTA and TEM analysis. Therefore, the 
described protocol was used for all subsequent release procedures from EV-MAP. 
Minimizing non-specific interactions through blocking and washing buffers. Lower flow 
rates improve recovery of EVs using mAb-decorated capture surfaces (as seen in Figure 26) 
because they increase the residence time thereby giving EVs more time to diffuse to the device 
surfaces. However, the lower flow rates also can render mechanical fluidic disruption unable to 
remove any nonspecifically bound EVs or other biological particles such as proteins or 
membrane aggregates from the device. Chemical passivation of the surfaces through a blocking 
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buffer could mitigate these limitations by keeping nonspecific entities from binding, while 
stringent washing after sample infusion could remove nonspecific particles previously bound.  
 Two blocking buffers, 1% BSA and 1% BSA supplemented with 1% PVP-40 
(polyvinylpyrrolidone, 40 kDa) were investigated in their ability to minimize non-specific 
binding. BSA passivates the surface by binding to any sites unoccupied by antibodies or any sites 
where the antibody is conjugated with the Fab region or antigen-binding region facing toward the 
surface, thereby preventing nonspecific particles from binding [214]. BSA is commonly used as 
a blocking agent in immunostaining, western blotting, or ELISA. PVP-40 is a hydrophilic 
polymer-based blocking agent used in western blotting [215] as well as RNA blotting as part of 
Denhardt’s blocking solution for membrane-based hybridization. It’s superhydrophilicity allows 
for blocking of hydrophobic interactions. The same buffer used in blocking the surface or 0.2% 
Tween 20® was implemented to wash the EV-MAP devices after affinity selection. Tween 20® 
is a nonionic surfactant routinely used in western blotting and immunostaining procedures to 
wash away weak particle-surface interactions. 
 To test the efficiency of these blocking and washing buffers, 500 μL of donor plasma was 
infused into anti-EpCAM and anti-IgG2A isotype decorated devices. These donor samples came 
from Bioreclamation and were only tested for the presence of infectious diseases. These samples 
were only used in assay optimization as they do not necessarily reflect healthy individuals as no 
other medical information is known. The affinity-purified EVs were proteolytically released via 
0.2% proteinase K for NTA. The nanoparticle concentrations were then compared from the two 
mAb fractions, with the isotype serving as a nonspecific control. Many microfluidic devices have 
used isotypes during development to optimize affinity-capture of EVs [119, 163, 193, 216]. To 
determine the number of specifically bound particles, it was assumed that the anti-EpCAM 
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devices would include both specifically isolated EVs and nonspecific particles, with the 
nonspecific EVs quantitated based on the EV concentration measured from the isotype control 
devices. The number of specific EVs was then defined as: 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑎𝑙𝑙𝑦 𝑏𝑜𝑢𝑛𝑑 𝐸𝑉𝑠 = 𝐸𝑉𝐸𝑝𝐶𝐴𝑀 − 𝐸𝑉𝑖𝑠𝑜𝑡𝑦𝑝𝑒  (Eq. 11)  
 When assessing the NTA results, high levels of nonspecific nanoparticles (NPs) were 
found in the isotype control blocked and washed with only 1% BSA (Figure 35). To determine 
whether the non-specific binding was due to electrostatic interactions, the salt concentration of 
the washing buffer was increased to 1 M. However, a high background of nonspecific NPs was 
still observed (Figure 35). The high non-specific binding present when using a high-salt wash 
suggested the non-specific interactions to be hydrophobic in nature as opposed to electrostatic. 
 
NTA NP concentration for either an anti-EpCAM or IgG2A isotype immobilized device washed with either a high 
salt buffer (1 M) or the same buffer used to block the devices (in this case 1% BSA in PBS). EVs were released off 
the devices through proteolytic digestion with 0.2% proteinase K and 10 min sonication. Five-hundred µL of donor 
plasma was processed. These devices were processed within the same experiment and show both BSA alone and 
high salt as a washing step result in high levels of nonspecific binding, as large EV concentrations occurred in both 

























ed EpCAM Isotype IgG2A
Washing:
Blocking: 1% BSA
Figure 35. Effect of high salt or 1% BSA wash on nonspecific binding measured through NTA NP concentration. 
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 We next incorporated 0.2% Tween 20® into the washing buffer, which drastically 
decreased the nanoparticle concentrations (Figure 36) by washing away nonspecific particles 
after initial binding to the surface. However, only 2x109 NPs/mL were specifically bound. It was 
hypothesized that the nonspecific fraction was competing for binding sites to the mAbs, shifting 
the focus toward optimizing the blocking buffer to improve passivation of the antibody surfaces 









































Blocking: 1% BSA 1% BSA/1% PVP-40
1% BSA 0.2% TWEEN20™ 1% BSA 0.2% TWEEN20™
Five-hundred µL of four donor plasma samples were processed through the EV-MAP assay to compare the level of 
nonspecific binding, determined through the isotype control (IgG2
A
), to the NP concentrations resulting from 
specific anti-EpCAM isolation. Different combinations including blocking buffers of either 1% BSA in PBS or 1% 
BSA/1% PVP-40 in PBS and the same buffer as a washing agent or 0.2% Tween 20® in TBS were tested for each 
donor sample processed through EV-MAP. Data labels are included to show the number of specific NPs that could 
be calculated from the number of nonspecific NPs based on Eq. 11. The blocking and washing combination of 1% 
BSA and 0.2% Tween 20® produced the lowest nonspecific background of EVs. However, the combination of 1% 
BSA/1% PVP-40 and 0.2% Tween 20® resulted in low nonspecific binding and increased the number of specific 
NPs. 
Figure 36. NTA NP concentration measurements for various blocking and washing combinations of EV-MAP. 
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subsequent 0.2% Tween 20® washing step increased the concentration of specific nanoparticles 
up to 3x109  NPs/mL of plasma (Figure 36). Therefore, the blocking and washing buffer 
combination of 1% PVP-40/1% BSA in PBS and 0.2% Tween 20® in TBS was found to both 
decrease the nonspecific binding while increasing the specific EV yield when compared to other 
buffer combinations. This optimum combination was then used for all subsequent EV-MAP 
assays.  
 
NTA-derived NP size distributions of anti-EpCAM and isotype EV fractions isolated from 500 µL of a donor 
plasma processed through EV-MAP using various blocking and washing combinations. A shift in NP size is 
apparent with the decrease of nonspecific NPs. The bulk NP population first consisting mainly of particles from 
150-200 nm spread to a more heterogeneous distribution with improved blocking and washing buffer schemes. 
Minimal particles were present in the background of PBS and proteinase K (bottom right graph).TBST refers to 
0.2% Tween 20® in tris-buffer saline (TBS) 
Figure 37. Size distribution of EVs processed through EV-MAP by various blocking and washing combinations. 
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NTA also provided size distribution measurements, showing a shift in the NP size when 
various blocking and washing combinations were employed (Figure 37). Initially, with high 
levels of non-specific binding still present, a population mainly centered around 150-200nm was 
observed. This peak decreased with the decrease of non-specific EVs, better separating the 
heterogeneous mixture of EVs ranging up to ~400 nm in size. Through this observation it is 
suggested that most nonspecific particles are around 150-200 nm, with the heterogeneity of the 
specific population confounded due to this background. 
2.2.5 EV-MAP validation through breast cancer cell lines 
Validation of EV isolation from breast cancer cell lines through TEM and quantification 
using NTA. Two breast cancer cell lines were cultured in EV-depleted FBS: MCF7 cells 
representing an epithelial phenotype – EpCAM(+)/FAPα(-) – and mesenchymal-like Hs578T 
cells – EpCAM(low)/FAPα(+) [98]. These cell lines provided a controlled sample for verifying 
the isolation of EVs from clinically significant sources consisting of either epithelial cancer cells 
or mesenchymal cells. In the body, epithelial cells may transition into a mesenchymal phenotype 
and in the process lose expression of cell adhesion proteins and gain mesenchymal 
characteristics such as expression of proteins involved in cell motility and degradation of 
extracellular matrices[53]. Because of this phenotypic change, mesenchymal cells show 
increased ability to invade surrounding local tissue and could even promote metastasis. 
To isolate EVs from the conditioned cell media, EV-MAP devices were either modified 
with anti-EpCAM or anti-FAPα mAb to selectively capture EVs of either mesenchymal or 
epithelial origin. Several studies have targeted the epithelial cell adhesion molecule (EpCAM) as 
a method of isolating epithelial-derived EVs, particularly in cancer patient samples [121, 185, 
186]. EpCAM is an outer membrane protein found on epithelial cells that assists in cell-to-cell 
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adhesion. In breast cancer, where 90% of cases originate in epithelial tissue [217], the anti-
EpCAM mAb serves as a suitable method of isolating disease-specific EVs. EpCAM has 
successfully been employed for isolating CTCs from whole blood, having been incorporated as a 
target molecule in the FDA approved CTC CellSearch System assay™.  
It is now known that the sole selection of EpCAM-containing biomarkers can 
underrepresent the full landscape of cell types resident within a tumor, or in this case EV types. 
Cells undergoing the epithelial-to-mesenchymal transition (EMT) lose characteristics of an 
epithelial phenotype and gain mesenchymal features including the notably lower expression of 
EpCAM [98]. One study showed the selection of mesenchymal-associated fibroblast activation 
protein alpha (FAPα) circulating tumor cells (CTCs) to be an orthogonal marker compared to 
EpCAM selection by observing 90% of the selected CTC cells to show no co-expression of these 
antigens. FAPα is a protein found on the membrane of reactive stromal fibroblasts, particularly 
in epithelial cancers, and promotes tumor growth and metastasis [218]. The addition of FAPα 
selection has resulted in a clinical sensitivity of 100% for several metastatic cancer types [98]. 
To ensure the selective capture of all EVs originating from breast cancer cells, both anti-FAPα 
and anti-EpCAM mAbs were used in this study as the selection mAbs. 
Isotypes were also used to interrogate the level of non-specific binding in the EV-MAP 
from a controlled sample (e.g. media). These isotypes have the same structure and come from the 
same class and subclass as a specific antibody but differ in their variable (Fab) region, ensuring 
that they do not bind to the antigen of interest. Isotypes have previously been used as a method 
of assessing the specificity of microfluidic EV isolation assays [121, 190, 191].   
For EV isolation, 500 μL of conditioned culture media was processed through either an 
anti-EpCAM, anti-FAPα, or IgG2A isotype immobilized EV-MAP device. IgG2A should show 
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nonspecific binding artifacts in the assay as the Fab region is not specific to any antigens found 
in humans. Affinity-selected EVs were released from the capture surface via digestion with 0.2% 
proteinase K for an incubation time of 30 min at 37° C and subsequent 10 min sonication. 
Released EVs were then quantified for size and concentration using NTA (Figure 38A, B). The 
released fractions were also analyzed by TEM (Figure 39) to assess the morphology of particles 
detected by NTA. 
The size of isolated EVs ranged from 30 – 300 nm with the average size in all fractions 
~125 nm (Figure 38A). The NTA results from the EV-MAP processed MCF7 media showed 
more than twice the number of nanoparticles captured on the anti-EpCAM selecting device, with 
equivalent concentrations between the anti-FAPα and nonspecific IgG2A control (Figure 38B). 
This trend aligns well with the cell line’s epithelial phenotype creating an EpCAM(+) and 
FAPα(-) expression for the MCF7 cell line [219]. NTA detected slightly more nanoparticles on 
the anti-EpCAM fraction from the Hs578T conditioned media and relatively none above the 
nonspecific background in the anti-FAPα fraction. EVs were expected to be captured in both the 
anti-FAPα and anti-EpCAM fractions as this cell line is known to express both antigens. The low 
number of EVs captured in the anti-FAPα fraction could be attributed to the expression of 
isoforms of the FAP protein [220]. Ten different mRNA transcripts are known to produce FAP 
isoforms from alternative splicing (http://www.ncbi. nlm.nih.gov/IEB/Research/Acembly/av.cgi? 
Db=human&c=Gene&1=FAP). One known isoforms is 27 kD [220] and resides inside the 
cytosol and therefore if expressed, could not complex with the mAbs on the surface of the 
device. Further investigation into FAP isoforms is required to understand their subcellular 




When analyzing the TEM images, EVs were observed with the traditional “cup-shape” 
morphology (Figure 39). Almost no particles were present in the TEM images from the isotype 
fractions. This suggests that the 2x108 nanoparticles/mL concentration observed through NTA 
was inherent background associated with the NTA detection method. Furthermore, the 
observation of EVs in the anti-FAPα fraction from the Hs578T cell line media through TEM 
suggests that the concentration was too low to discern from this NTA background. 
Size distribution and concentration of EVs isolated from MCF7 and Hs578T conditioned media using EV-MAP. 
Five-hundred µL of conditioned media was processed through anti-EpCAM, anti-FAPα, and IgG2A isotype 
immobilized devices. EVs were released through 0.2% proteinase K digestion and subsequent 10 min sonication. 
(A) The line graphs illustrate the size distribution within the release fractions as measured by NTA. (B) The bar 
graph shows the average concentration of particles found in each isolated fraction through NTA from 5 replicate 















































































Figure 38. Size and concentration of EVs isolated by EV-MAP from MCF7 and Hs578T cell lines. 
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NTA is based on the concept of Brownian motion and laser light scattering from 
particles. This pattern is recorded and allows the NTA software to track the particle’s distance 
traveled to determine the diffusion coefficient (eq. 12) which is then applied in the Einstein-








  (Eq. 13) 
The diffusion coefficient 𝐷 incorporates both the distance a particle moves in the 𝑥, 𝑦, and 𝑧 
directions and the time 𝑡 required to move that distance. The diameter 𝑑 of the particle is then 
back calculated from the known diffusion coefficient 𝐷, Boltzmann constant 𝑘𝑏, temperature 𝑇, 
and viscosity 𝜂. Most NTA instruments can detect any particle ≥70nm [221], meaning the 
procedure counts anything above 70 nm moving in the solution irrespective of whether it is an 
TEM images of EpCAM(+) and FAPα(+) EVs as well as images of the isotype fractions isolated from 500 µL of 
Hs578T or MCF7 conditioned media processed through anti-EpCAM, anti-FAPα, and IgG2A isotype immobilized 
EV-MAP devices and released using proteolytic digestion with 0.2% proteinase K. Scale bars are 500 nm. 
Figure 39. TEM images of EVs isolated by EV-MAP from Hs578T and MCF7 cell lines. 
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EV when determining concentration. Studies have shown that when particles are ≥400nm is size, 
they are often counted multiple times by NTA[221-223] and thereby overestimate the overall 
concentration potentially by over 1 billion NPS/mL[221]. Further, because NTA only tracks 
particles based on light scatter it cannot discern EVs from other particles present in samples such 
as proteins, protein aggregates, etc. Arraud et al. compared EV concentrations from NTA to a 
custom method of immunogold labeling through the presence of Annexin V known to reside in 
the membrane of all EVs, then centrifuging the EVs onto TEM grids for manual counting of 
particles [163]. A large disparity was found, from ~52,000 EVs/µL detected in healthy plasma 
from cryo-TEM gold nanoparticle labeling compared to 109 EVs/µL of plasma reported from 
NTA results within the literature [164].  
EV mRNA profiling from EV-MAP isolated Breast cancer cell line EVs.Conducting mRNA 
expression profiling on breast cancer patient samples identifies the molecular subtype of the 
disease, enabling physicians to stratify patients based on the associated predicted prognosis and 
treatment response. FDA approved commercial tests exist such as the Prosigna® or Oncotype 
Dx® for analyzing mRNA from breast cancer tissue, with this material currently obtained from a 
solid tissue sample and often comes from the same tissue sample used first for 
immunohistochemistry and morphological as well as nuclear assessment of cells. Pathologists 
therefore may not have enough sample remaining to perform mRNA analysis. Even if they 
procure enough mRNA for the assays, the sample only comes from a single biopsy of the tumor, 
potentially misrepresenting the heterogeneity of the disease. EVs may create an alternative 
source for mRNA because their cell of origin, such as a cancer cell, can transfer mRNA [133] 
into the EVs. A simple blood draw would then be required to obtain sample as opposed to an 
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invasive biopsy. However, it is first important to assess whether EVs package mRNA from their 
cell of origin by comparing EV and cell mRNA expression profiles. 
EV mRNA expression profiling was performed on Hs578T and MCF7 EVs isolated using 
EV-MAP. Five-hundred μL of Hs578T cell media was processed through EV-MAP devices 
conjugated with either anti-EpCAM or anti-FAPα mAbs. The captured EVs were lysed on-chip 
for TRNA extraction and purification. In procuring cell mRNA, media either cultured in EV-
depleted FBS or regular FBS was centrifuged at 300g for 10 min to pellet the cells for direct lysis 
and the TRNA extracted using the same RNA purification kit. TRNA aliquots of 2 µL were 
reverse transcribed using poly(dT) primers to generate cDNA only from mRNA for downstream 
ddPCR.  
ddPCR has been used to assess the miRNA content [224, 225] or mRNA expression [132, 
162, 225] in various EV populations. Digital PCR (dPCR) employs absolute quantification by 
partitioning template DNA or cDNA into tens of thousands of nanoliter-sized replicate reactions, 
where some contain the target of interest and others do not. This distribution of target template 
into small confined volumes increases the fluorescence signal generated from the PCR reactions, 
allowing for sensitive analysis of a single copy of target template in one of the many “reactions” 
or droplets. These reactions are then subjected to end-point PCR and results analyzed through 
fluorescence signal only emitted from reaction droplets containing one or more copies of the 
cDNA, correlating with a positive outcome. The fraction of positive reactions is then interpreted 
using Poisson statistics [226]. The use of Poisson statistics takes into account that a single 
reaction could have multiple copies of target sequence, with a higher number of positive 
reactions increasing this probability [226]. ddPCR specifically partitions the template from one 
reaction volume into aqueous droplets composed of a water-oil emulsion, decreasing the time 
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needed for reaction set-up thereby increasing throughput. The relationship between the fraction 
of positive droplets and the resulting copies/µL detected when applying the Poisson distribution 
was previously shown in Figure 21 from the ddPCR section under Methods (see Eq. 1). 
Quantitative PCR (qPCR) or real-time PCR is commonly used for analyzing extracellular 
RNA [125, 162, 224, 227-230], but has disadvantages compared to ddPCR. Unlike ddPCR, 
qPCR does not provide absolute quantification of copies and rather determines the rate of target 
amplification based on a cycle threshold (Ct) value in comparison to a standard calibration curve 
that will result in relative expression of the target. These calibration curves may increase the 
variation in assay results between different laboratories particularly if different materials are 
chosen for standards. Internal variance may also occur due to potential changes within the 
calibration curve over time [231]. Optimization of all primer pairs used is also important to 
ensure amplification efficiency is consistent, with poor optimization contributing to low 
reproducibility of results by creating inaccurate Ct values [232]. 
ddPCR is not dependent on the amplification or reaction efficiency because it measures 
the expression of target molecules at the end of all PCR cycles. For this reason, the procedure 
also requires no calibration curves, decreasing the external and internal variance[233] compared 
to qPCR. ddPCR is also associated with an increased ability to analyze low-abundance targets 
because it partitions the targets into small nanoliter-sized volumes for subsequent PCR within the 
confined space, increasing the positive signal generated. Both the lower limit of quantification 
and the lower variance are important when assessing often low disease-associated gene 




Table 13. Proteins encoded by genes chosen for the EV-MAP mRNA expression panel along with their function. 
 
The gene panel chosen for EV-mRNA expression profiling included an assortment of 
epithelial and mesenchymal-associated genes to differentiate between the two cell lines based on 
phenotypic orthogonality (Table 13). This panel contained epithelial cell adhesion molecule 
(EpCAM), cytokeratin 19 (CK19), fibroblast activation protein α (FAPα), vimentin (VIM), and 
interleukin 8 (IL8). The panel also included well-established breast cancer stem cell markers 
CD44 and CD24, as they distinctly indicate the originating cell line and may predict the risk of 
distant metastasis [234]. Hs578T cells express CD44 and low expression of CD24 
(CD44(+)/CD24(low)), with this cell line presenting a mesenchymal phenotype known to 
cell origins of 
high expression gene function of encoded protein 
epithelial 
phenotype EpCAM 
Transmembrane glycoprotein expressed in epithelia to facilitate Ca
2+
-
independent cell-to-cell adhesion and involved in proliferation, cell 
migration, and differentiation. 
CK19 





Membrane gelatinase apart of the serine protease family expressed in reactive 
stromal fibroblasts and facilitates extracellular matrix degradation to increase 
cell motility and allow them to move through surrounding tissue. 
VIM 
Type III intermediate filament protein making up a large portion of the 
cytoskeleton in mesenchymal cells to maintain cell structure. 
IL8 
Protein of the chemokine family often secreted by neutrophils to help guide 
these cells to the infection, also found to promote angiogenesis. 
all EVs 
CD81 
Protein  from the tetraspanin family found on the cell surface to facilitate 






Sialoglycoprotein expressed on granulocytes and B cells to mediate growth 
and differentiation signals. 
CD44 
Transmembrane glycoprotein facilitating cell-cell interactions, adhesion, and 
migration. Used in many cellular functions such as lymphocyte activation, 
hematopoiesis, and tumor metastasis. 
List of genes included in gene panel for analysis of breast cancer cell line mRNA expression. Each has a brief 
description of the function and protein encoded, with all genes split amongst categories based on the cell type with 




facilitate tumor progression or potentially metastasis. This cell line highly correlates with the 
claudin-low subtype based on gene expression profiling [235], fitting with the mesenchymal-like 
phenotypic nature of this subtype. MCF7 cells show expression of both CD44 and CD24 
(CD44(+)/CD24(+)), and the cell line shows gene expression profiling most similar to the 
luminal B breast cancer subtype[235]. Expression of the tetraspanin CD81 was also examined as 
it is a general EV marker. 
The mRNA expression profiles were determined by normalizing the copy results from 
ddPCR to the mass of total RNA (TRNA) input into the reverse transcription (RT) reaction (see 
Eq. 2 in ddPCR section of Methods). The dilution of the RT product refers to any initial dilution 
of the cDNA sample before putting into the PCR reaction as well as the 1/10th dilution inherent 
when taking 2.2 µL of cDNA from a 20 µL RT reaction. As an example, if 2.2 µL is directly 
taken from the 20 µL RT reaction then the dilution factor for this cDNA would be ~9 (20 µL RT 
reaction/2.2 µL cDNA taken out). Furthermore, because this is normalized to the TRNA mass 
input into RT, the TRNA concentration provided by HS RNA Tape analysis was multiplied by 
the 2 µL TRNA volume added to the RT reaction. 
The anti-EpCAM and anti-FAPα EV mRNA fractions from the MCF7 cell line both 
showed high expression of the epithelial-associated gene CK19, correlating well with the high 
expression also observed in the MCF7 cells (Figure 40A). However, mesenchymal signatures 
are also present in both fractions through expression of IL8 and FAPα. This suggests that EVs 
may preferentially package these low-expressed mRNA transcripts compared to their cells of 
origin. Other studies have shown discrepancy between breast cancer cells and their secreted EV’s 
gene expression[134, 236], with one finding only a 5% concordance between mRNA transcripts 
overexpressed in tumor cells versus EVs[134] It is interesting that any FAPα(+) EVs were 
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isolated from the MCF7 epithelial phenotype cell line, as this cell line does not express 
FAPα[237]. However, as stated previously, alternative splices of the FAP gene exist [220] and 
few of them have been extensively studied. Little research has been conducted to assess the 
expression of each splice variant in the MCF7 cell line, so it is unknown whether a splice variant 
encoding a different FAP isoform could be expressed. Lastly, the MCF7 EVs showed lower 
expression of the pan-EV protein CD81 when compared to the MCF7 cells. This low expression 
of CD81 in breast cancer EVs was also observed in another study performing differential 
ultracentrifugation on EVs and assessing the pellet protein contents [238]. Therefore, it is 
important to note that CD81 is not highly expressed in all EVs irrespective of their cell origin. 
Overall, several differences in expression profiles between the MCF7 cells and MCF7 
EVs were observed. Discrepancy between host cell and EV mRNA expressions has previously 
been observed in studies using microarray analysis, where certain transcripts were highly 
expressed in EVs compared to the low or even lack of expression observed in the cell of origin 
[115, 134]. Therefore, it is not impossible for EVs to differ in expression of certain genes from 
their cell of origin. 
Hs578T EVs isolated using the anti-EpCAM and anti-FAPα immobilized devices showed 
low expression of epithelial-associated genes (EpCAM and CK19) (Figure 40B), as was 
expected due to the mesenchymal phenotype of the cell line which also correlated with the 
mRNA expression pattern observed from Hs578T cell mRNA (Figure 40B). An increase in 
copies/ng of mRNA was observed across all genes within the panel for the anti-FAPα fraction 
compared to the anti-EpCAM EV fraction, correlating to the FAPα(+)/EpCAM(low) expression 
characteristic of the Hs578T cell.  
110 
 
To accurately compare the EV gene expression profile to that of cells, it was important to 
determine how the loss of bovine EVs could affect the gene expression of cells, especially with 
previous studies finding human cancer cell lines transitioned into EV-depleted FBS to decrease 
in their growth due to the lack of bovine EV-uptake [206, 239]. The profile of the mRNA from 
the Hs578T cells cultured in EV-depleted FBS showed little difference when compared to the 
profile from cells cultured in regular FBS (Figure 40B), with both mRNA fractions still 
exhibiting the expected mesenchymal-like phenotype with high expression of mesenchymal 
associated genes such as VIM, FAPα, and IL8 and low expression of epithelial associated genes 
EpCAM and CK19. The MCF7 cells cultured in EV-depleted FBS and cells cultured in regular 
mRNA expression profiling of (A) MCF7 and (B) Hs578T EVs isolated from conditioned media by the three-bed 
EV-MAP device immobilized with either anti-EpCAM or FAPα antibody for comparison with the mRNA 
expression from their cells of origin. EVs isolated on the device were lysed on-chip to extract and purify TRNA, 
where 2 µL of the 6.5 µL elution volume was used for RT-ddPCR. Cells were centrifuged at 300g for 10 min and 
then directly lysed for TRNA extraction, with 1 µg added for RT then subsequent ddPCR. The expression profiles 
of the selectively captured EVs were set to the same scale based on the highest number of copies observed and 
normalized to the TRNA mass input into the RT reaction, accounting for subsequent dilutions (Eq. 2). The cell 
mRNA expression from either culture media grown in regular FBS or conditioned with EV-depleted FBS were 



























MCF7 cells MCF7 EVs Hs578T cells Hs578T EVs
copies/ng copies/ng
0 50% Max 0 1,500 3,500 0 50% Max 0 50,000 107
Figure 40. mRNA expression profiling of EVs isolated by EV-MAP from MCF7 and Hs578T conditioned media. 
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FBS both showed the expected epithelial phenotypic expression profile with low expression of 
mesenchymal-associated VIM, FAPα, and IL8 genes. The MCF7 cells cultured in EV-depleted 
FBS showed markedly higher expression of CD24 compared to the cells cultured in regular FBS. 
However, the MCF7 cell line is known to express both CD24 and CD44 (CD24(+)/CD44(+)) so 
this change in expression still aligns with the expected gene profile. This similarity in mRNA 
profiles provides evidence that EV depletion of the FBS does not mask or alter the expression 
profiles from what is expected for either the epithelial or mesenchymal cell phenotype. 
Evaluation of EV-MAP specificity using donor plasma samples.After optimizing the blocking 
and washing buffers to minimize nonspecific binding, it was important to assess the specificity 
of the EV-MAP assay resulting from processing a complex sample such as plasma. To do this, 
mRNA expression profiles were compared between the specific capture of EVs and nonspecific 
background represented by EV mRNA isolated from the isotype EV-MAP devices. Furthermore, 
the specific EV-MAP isolation procedure using anti-EpCAM and anti-FAPα antibodies was also 
compared to the bulk isolation of all EV populations represented through using a pan-EV 
antibody anti-CD81. 
 In order to assess the specificity of the EV-MAP assay, 500 µL of pooled donor samples 
were infused into two sets of devices that were anti-EpCAM, anti-FAPα, anti-CD81, and IgG2B 
mAb functionalized. Many microfluidic affinity-based EV isolation platforms focus on the 
capture of all EVs, targeting pan-EV markers such as tetraspanins CD81, CD63, or CD9 [190-
192]. The isolation of all EVs may confound mRNA expression differences that could otherwise 
prove clinically valuable, similar to the loss of expression of disease-associated genes previously 
seen [162].Therefore, anti-CD81 was used to investigate the result of isolating bulk EVs 
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compared to the specific epithelial or mesenchymal EV approach used in the EV-MAP assay. 
IgG2B is the isotype to anti-CD81 and therefore used to assess the assay specificity.  
Five-hundred µL of a pooled donor sample was processed through either anti-EpCAM, anti-FAPα, anti-CD81, or 
IgG2b immobilized devices. (A) Isolated EVs from one set of devices were released by 0.2% proteinase K digestion 
for TEM imaging. The characteristic cup-shape morphology of EVs was observed in all fractions, including the 
isotype. All scale bars are 100 nm. (B) A separate set of EV-MAP devices was processed in parallel using the same 
pooled donor sample for EV lysis on-chip and TRNA purification. TRNA was pooled from three devices 
immobilized with the same mAb to increase TRNA yield closer to the HS RNA Tape quantification range (500 
pg/µL). All fractions contained TRNA with sizing similar to that found in EVs. (C) Two µL of the TRNA was then 
added to an RT reaction, with 2.2 µL of the cDNA product input into-ddPCR for mRNA expression profiling. The 
total copy results were normalized to the ng of TRNA input into RT (Eq. 2 in ddPCR section of 2.2), accounting for 
any initial cDNA sample dilutions as well as the dilution of the TRNA into the total 20 µL RT reaction. The isotype 
fraction resulted in negligible copies of the genes targeted in the EV-MAP panel, creating a specificity of 99 ± 1%. 






































































EV-MAP devices were all blocked with 1% BSA/1% PVP-40 and washed with 0.2% 
Tween 20®. After the washing step, one set of devices was treated with proteinase K for release 
of EVs for TEM imaging (Figure 41A) while another set of devices was subjected to TRNA 
purification (Figure 41B) and subsequent RT-ddPCR analysis (Figure 41C). TRNA from three 
EV-MAP devices were pooled together for RT-ddPCR and HS RNA Tape analysis. 
TEM images of the isotype fraction did show the presence of EVs. The majority of EVs 
observed from the isotype fraction were small exhibiting a diameter <30 nm (Figure 41A). The 
presence of EVs in the isotype fraction was verified by the existence of TRNA (Figure 41B). All 
TRNA traces were indicative of EVs as the majority of the sizes ranged from 200 to 500 nt.  
The non-specific EVs captured in the isotype fraction contained negligible copies/ng for 
the target genes in the panel, therefore showing the assay results in a high specificity of 99 ± 1%  
when analyzing these target genes. This is important because it shows that the expression of 
disease-associated genes and differences of gene expression between different disease-associated 
EV populations such as epithelial or mesenchymal-derived EVs are not masked and easily 
delineated through EV-MAP. This suggests that EV-MAP could provide clinically relevant 
mRNA expression information that could prove beneficial in the breast cancer clinical pathway 
which already uses transcriptome analysis in disease diagnosis. 
When comparing the bulk isolation of EVs to the specific isolation of epithelial and 
mesenchymal derived EVs, the anti-CD81 bulk fraction masked the epithelial phenotype 
observed from the EpCAM(+) EVs through negligible expression of CK19. The anti-CD81 
fraction instead only presented a mesenchymal-like gene profile as was also seen from the anti-
FAPα fraction. Furthermore, expression differences between genes within the anti-CD81 fraction 
were less pronounced in comparison to the specific isolation of FAPα EVs. Both the masking of 
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the epithelial phenotypic profile seen from the specific anti-EpCAM isolated EVs and the 
confounding of expression differences between the genes found in the anti-CD81 fraction 
suggest that the capture of all EVs may confound disease-associated mRNA expression and 
expression differences which aligns with a previous study assessing bulk EV isolation through 
differential ultracentrifugation[162].  
2.2.6 EV-MAP processing of diseased and healthy control samples.Healthy control samples 
and breast cancer patient samples were received from KUMC. Women coming in for routine 
mammograms and known to have no current diagnosis of cancer were provided as healthy 
controls. The breast cancer samples were either banked in the KUMC Biorepository (collected in 
2017) or extracted from patients at the Indian Creek clinic at KUMC (collected in 2019). A 
distribution of both receptor status, stage, and even disease diagnosis was found within the 
patient cohort (Table A1). Most patients had received some form of treatment prior to the blood 
draw and were older than 55 years of age.  
 Five-hundred μL of these samples were processed through the anti-EpCAM and anti-
FAPα EV-MAP devices, using the optimized blocking and washing buffer compositions of 1% 
PVP-40/1% BSA in PBS and 0.2% Tween 20® in TBS, respectively. After processing, EVs 
were lysed off-chip for TRNA purification and subsequent RT-ddPCR analysis to compare gene 
expression profiles. Three healthy controls and ten patient samples were processed. 
None of the healthy controls or patient samples resulted in a TRNA concentration 
detectable by HS RNA Tape ( limit of detection = 100 pg/μL). All EV TRNA samples were 
input into RT (2 µL of TRNA) for ddPCR analysis. To conserve expensive ddPCR resources, 
patient and healthy control cDNA was first assessed through a smaller screening panel of genes. 
CK19, VIM, and CD81 were chosen because together they characterized both the epithelial and 
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mesenchymal phenotype of interest as well as a general EV marker. Low copy numbers using 
ddPCR were observed (Example copy numbers shown in Table 14 and Figure 42) with a few 
genes in some samples not showing copy levels above the negative RT background or showing 
copy levels below the limit-of-detection of ddPCR (Figure 42) (limit-of-detection empirically 
determined as 4 copies [240]).  












CK19 0 0 3.4 0 
VIM 3.4 1.6 5 0 
CD81 0 0 4.8 3 
 
Example of ddPCR raw total copy counts from 20 μL PCR reactions from a healthy and patient sample using the 
shortened gene panel, with negative RT results subtracted. The limit of detection for ddPCR is 4 total copies. P5 
patient information is provided in Table A2 of the appendix. 
Each column is scaled only to their own highest copy number. The copy numbers in the heat map refer to the total 
raw copies found in the 20 µL ddPCR reactions for each gene, with negative RT results subtracted. Several genes are 
shown below the limit of detection of droplet ( >4 total copies). 


















Researchers have rarely performed transcriptome analysis of EVs compared to the 
breadth of studies analyzing the EV proteome. Several reasons exist as to why researchers have 
shied away from analyzing EV mRNA. Firstly, as discussed in Chapter 1, only up to 10% of EV 
TRNA is associated with any RNA species other than rRNA fragments, with only 0.25% of 
TRNA found to be mRNA when RNA sequencing was performed for glioma stem cell derived 
EVs[148]. Furthermore, most mRNA found in EVs is fragmented[133] and therefore may not 
properly amplify product after cDNA synthesis. Instead, most EV isolation research has focused 
on comparing the concentration of EVs between healthy and breast cancer patient samples [229, 
241], particularly in developing microfluidic EV isolation platforms for clinical applications 
[128, 129, 242]. Only analyzing the quantity of EVs lacks clinical applicability compared to 
mRNA analysis because the FDA would need to approve the use of such a novel biomarker in 
addition to the new technology, requiring extensive clinical trials.  
However, streamlining the new technology with a diagnostic test already used for a 
disease could automatically show clinical relevance. As an example, EV transcriptome analysis 
from immunoaffinity isolated EVs was chosen as the target of interest in this study because tests 
implementing mRNA expression analysis are already incorporated into clinical care for breast 
cancer management through FDA approved tests such as the Prosigna® or Oncotype DX® 




Chapter 3. Summary and future directions 
An extracellular vesicle microfluidic affinity purification (EV-MAP) device consisting of three 
beds serially connected and populated with micropillars was developed. Through Monte Carlo 
simulations incorporating convection, diffusional dynamics, and Ab-binding kinetics, the EV-
MAP device theoretically achieved 80% recovery of EVs at the flow rate of 2.1 µL/min used in 
this study. For off-line EV analysis using TEM and NTA, a release procedure using 0.2% 
proteinase K and 10 min sonication was developed which proved to maintain the integrity of the 
EVs through no evidence of lysis and produce a release efficiency of 99 ±1%. Optimization of 
the EV-MAP assay for EV isolation required investigating the best blocking and washing buffer 
combination to mitigate nonspecific binding. A blocking buffer composition of 1% BSA/1% 
PVP-40 in PBS and washing buffer of 0.2% Tween 20® produced the lowest number of 
nonspecific NPs as assessed through an isotype immobilized device. It also increased the number 
of specific particles captured by 1x108/mL when analyzed through NTA compared to other 
reagent combinations. 
 RT-ddPCR was performed on TRNA extracted from EVs isolated through the EV-MAP 
device to analyze mRNA expression profiles. EVs from Hs578T culture media conditioned in 
EV-depleted FBS showed similar mRNA profiles to that resulting from their cells of origin, 
suggesting that EVs could serve as an alternative or supplementary source of mRNA for breast 
cancer diagnosis currently implementing gene expression profiling for patient stratification and 
treatment decision-making. MCF7 EVs showed discordance from the MCF7 cell mRNA 
expression resulting in a combination of an epithelial and mesenchymal phenotype, suggesting 
that these mesenchymal genes may be preferentially packaged into MCF7 EVs compared to their 
cell of origin. The EV-MAP assay resulted in 99 ± 1% specificity to the target genes assessed 
through mRNA profiling of EVs from donor plasma by showing negligible gene copies resulting 
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from the isotype EV fraction. After optimizing the EV-MAP assay, healthy controls and patient 
samples were processed for mRNA expression profiling using RT-ddPCR. Extremely low copy 
numbers from both healthy control and disease plasma EVs were observed, with some genes 
either not showing above the negative RT background or not observed above the limit of 
detection for ddPCR (4 total copies or 0.2 copies/µL), suggesting that EVs may carry low masses 
of mRNA for the genes used in this study. 
Studies have been conducted to characterize the TRNA populations packaged into EVs. 
Wei et al. characterized both small and long RNA species through RNA sequencing of EVs 
derived from glioma stem cells, and found ~10% of TRNA from EVs was non-rRNA, with 
mRNA accounting for only 0.25% of the EV TRNA population [148]. Further, based on NTA 
results and TRNA mass, it was observed that 4.45 ag of TRNA is packaged into each EV. Taking 
these mass considerations into account, the mass input and output through the EV-MAP assay 
was calculated using certain assumptions supported by the literature (Figure 43). 
Through NTA results after EV release from the EV-MAP device(see Figure 38), an 
average of ~2x108 EVs were isolated from 500 µL of cell media. Assuming each EV contains 
4.45 ag of TRNA and empirically determining the efficiency of the Direct-zol Microprep Kit 
(Zymo) to be 41%, only 356 pg of TRNA could be secured from 1 EV-MAP device. When 
considering the TRNA is eluted in 6.5 µL, this will result in a TRNA concentration of ~55 
pg/µL. As noted above, the percentage of mRNA from TRNA found in an EV is 0.25%, which 
means that roughly 1 pg of mRNA will result from the EV-MAP assay. This is then diluted when 
added to the PCR cocktail, indicating 100,000 mRNA molecules may be extracted from 2x108 
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EVs by assuming the average mRNA packaged into EVs is 500 nt, supported by the size 
distribution observed from EV TRNA extracted in this study (see Figure 31 ). 
 Relative expression results procured through RNA sequencing were procured from the 
Gene Expression Omnibus database for MCF7 cells and applied to the number of total mRNA 
molecules calculated from 108 EVs (Table 15). This relative expression data was also used to 
determine the relative expression of target genes used in the EV-MAP assay for a single cell. In 
both contexts, there are some genes that are expressed at low levels and potentially show as 
silent with current expression profiling technology. However, the significant difference in 
 0.25% TRNA = 
mRNA 
*~4.45 ag of 















Max yield =  




mRNA Max yield = 
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Mass inputs and outputs through every step of the EV-MAP assay are calculated based on experimental results for 
the average number of EVs isolated through NTA (see Figure 38). From the number of EVs, the number of mRNA 
molecules can be calculated based upon the assumption that all mRNA is reverse transcribed into cDNA with 100% 
efficiency and an experimental study which found a single EV to hold ~ 4.5 ag of TRNA, with only 0.25% of EV 
TRNA amounting to mRNA[147]. These calculations were performed assuming the average mRNA molecule 
packaged into EVs is ~500 nt (see Figure 31). Finally, it is assumed that each ribonucleotide is ~ 330 g/mol. These 
calculations result in ~ 100,000 mRNA molecules from 2x10
8 
EVs. The TRNA recovery using the Directzol 
Microprep kit (Zymo) was empirically determined to be 41%. 
 
Figure 43. Flow chart depicting the mass yield from each step in the three-bed EV-MAP assay. 
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number of particles (one cell vs. over 10 million EVs) with little change in gene expression 
further highlights the mass limitations experienced in analyzing mRNA packaged into EVs. 
Table 15. mRNA expression of the target genes used for EV-MAP compared to the expression from a single cell. 
Gene Copy Number in 
3-bed device 
Copy 
Number in a 
Single Cell 
EpCAM 22.5 159 
CK19 154 1,086 
FAP 0.028 0.199 
VIM 0.21 1.47 
IL8 0.025 0.174 
CD81 9.81 69.2 
CD24 92.6 653 
CD44 7.75 54.7 
 
One method of increasing the mRNA mass yield in the EV-MAP assay is to increase the 
amount of EVs captured. Another version of the EV-MAP device contains 7 beds connected in 
parallel for high-throughput processing and a ~ 6-fold increase in surface area to increase EV 
capacity compared to our existing 3-bed device (Figure 44). This correlates to >500,000 mRNA 
molecules as opposed to the 100,000 isolated from EV-MAP (Table 16). The device has a 
Using MCF7 cell line mRNA sequencing data procured from the open access Gene Expression Omnibus (GEO) 
database, relative expressions of genes from 2x10
8 
EVs were calculated. The ~ 100,000 mRNA molecules procured 
through EV-MAP are not evenly distributed among every gene, with some genes having such a low expression they 
could not be detected through conventional expression profiling methods such as ddPCR. Further, when comparing 
the amount of gene copies from 2x10
8 
EVs to the gene copies resulting from a single cell using the same RNA 
sequencing data, the low mass limitations of mRNA in EVs becomes apparent as even one cell produces higher 




surface area of 38.57 cm2 with the same interpillar spacing of 10 µm designed for the EV-MAP 
3-bed device (Table 16).  
 
Table 16. Design parameters for the 3-bed and 7-bed EV-MAP devices. 
 




) 6.8 38.57 
Number of pillars 15,202 1,475,712 
Pillar dimensions 110 x 100 µm 10 x 10 x 50 µm 
Pillar spacing 10 µm 









7-bed EV-MAP (Biofluidica) 
The 7-bed design of the EV-MAP device also consists of micropillar arrays with 10 um spacing in between. 
However, the surface area is greatly increased by a factor of ~6, similarly increasing the EV load capacity.  
Figure 44. CAD schematics for the three-bed and seven-bed EV-MAP devices. 
CAD schematics for the three-bed and seven-bed version of the EV-MAP device. Both contain beds populated 
with micropillars. However, the beds in the three-bed device are serially connected while the seven-bed device 




Another method to increase copy number is through amplification of mRNA post-
processing. Whole transcriptome amplification (WTA) is a method of increasing cDNA by 
amplifying all mRNA molecules containing a poly-adenylated tail and can be performed on 
sample inputs as low as 100 fg. Figure 45 shows a general outline of the WTA procedure. 
Firstly, WTA synthesizes cDNA from mRNA using anchored poly(dT) primers to anneal at the 
3’ poly-A tail. Terminal deoxynucleotidyl transferase (TdT) then adds dATPs to the 3’ end of the 
cDNA. Exonuclease I treatment often precedes this step to degrade any competing ssDNA 
primers. A denaturation step separates the original mRNA template from the cDNA, allowing for 
a new batch of poly(dT) primers to anneal and extend the polyadenylated cDNA during PCR. 
 
Lower case n = number of either tyrosine or adenine added onto the molecule, with subscript n’s taking on a value 
based on the primer length used in the reactions. Black bar denotes mRNA, red denotes cDNA, and blue denotes 
PCR product. First, anchored poly(dT) primers anneal at the poly-A tail of mRNA to synthesize cDNA. Next, 
addition of Exonuclease I degrades remaining ssDNA primers that could anneal to the dATPs which are added to 
the 3’ end of the cDNA products through TdT so the sequence of both ends of the cDNA is known. The mRNA 
template is denatured from the cDNA to create a ssDNA template for PCR which uses another round of poly(dT) 
primers. Overall, this procedure then takes all starting mRNA with a poly-A tail and amplifies it to increase the 
Yield of transcripts of low expression before traditional PCR using specific primers. 
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Figure 45. General steps for WTA procedure. 
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 WTA was performed on mRNA to compare the copy results to standard cDNA synthesis 
(using Protoscript II, NEB). A combined TRNA mass of 17.1 µg from SKBR3 and MCF7 cells 
was purified to extract mRNA using the Dynabeads™ mRNA DIRECT™ purification kit 
(Invitrogen). Standard protocol was implemented with a few modifications, namely the inclusion 
of extra washing steps to ensure complete removal of remaining lithium dodecyl sulfate (LiDS) 
surfactant, known as a strong inhibitor for enzymatic reactions. Five-hundred pg of purified 
mRNA (recovered 173 ng mRNA in total or ~1% of TRNA) served as the starting material for 
both WTA that was carried out using the CellAmp™ Whole Transcriptome Amplification Kit 
Ver.2 (Takara) standard protocol and traditional cDNA synthesis or RT using the same kit 
previously mentioned for this study. Products were then submitted to ddPCR after diluting the 
RT or WTA material 30 times.  
 As suspected, the mRNA processed with WTA showed much higher copy numbers 
compared to cDNA synthesis alone (Figure 46A). More importantly, WTA did not bias the gene 
expression profile, showing the same expected epithelial genes to be highly expressed compared 
to mesenchymal phenotypic genes (Figure 46B). Copies from ddPCR were analyzed without 
normalizing to the input RNA as the same input masses were used for both procedures. In 
conclusion, WTA may increase input mass of target molecules otherwise present in low levels in 




 Future work should also include the translation of EV-MAP into currently FDA-approved 
gene expression profiling tests. The gene panel chosen for this study was designed based on 
orthogonal markers distinguishing mesenchymal and epithelial phenotypes, as the antibodies 
implemented captured these two distinct expression profiles and previous studies had used these 
genes to assess CTC molecular profiles from breast cancer patients, finding clinical significance 
in assessing both for treatment response or monitoring treatment[98]. The selection and 
expression of EVs based on phenotype was also chosen because the breast cancer intrinsic 
Each procedure started with 500pg of combined MCF7 and SKBR3 cell mRNA. Both procedures used Poly(dT) 
primers to synthesize cDNA from the poly-A tail of the mRNA. However, the WTA procedure also amplifies all 
cDNA synthesized from mRNA prior to the ddPCR. (A) Comparison of total copies produced after ddPCR of 
either the WTA or RT product, highlighting the higher expressions resulting from WTA vs. traditional RT. The 
color scale bar is based on the gene of highest expression within the entire panel. (B) Total copy data from both 
procedures analyzed separately to distinguish any differences in the expression profiles. WTA does not 
significantly affect the gene expression profiles, with expected epithelial genes still highly abundant and 
mesenchymal genes relatively silent. Each column is scaled to each procedure’s gene of highest expression 
thereby producing a percentage.  
Figure 46. mRNA expression profiling of PCR products from WTA or cDNA from traditional RT. 
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subtypes may be differentiated using these same phenotypes, with claudin-low showing a 
mesenchymal phenotype and Luminal A or B associated with a luminal epithelial phenotype. 
 However, these genes are not included in the FDA-approved Prosigna® and Oncotype 
Dx® test. Therefore, it would be critical to isolate EV TRNA using EV-MAP for mRNA 
expression profiling of the genes used in these tests. The Prosigna® assay uses the PAM50 gene 
panel and five reference genes, while the Oncotype Dx® tests only 16 genes specifically 
associated with proliferation and the invasive nature of cells [243], most of which are included in 
the PAM50 panel, and 5 reference genes. 
 To discuss one of the assays in further detail, the Prosigna® assay provides gene 
expression results through the relative abundance of mRNA transcripts. Fluorescent reporter 
probes and capture probes are hybridized to the TRNA. These captured transcripts are 
immobilized on a cartridge surface for clear detection of the barcode distinct to each reporter 
probe by nanoString nCounter technology. Prosigna® requires at least 12.5 ng/µL of TRNA 
from formalin fixed parrafin embedded tumor tissue to successfully perform the assay, thereby 
making the increase of EV mRNA yield either through the seven-bed EV-MAP device or 
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A1. Macro used for measuring EV-MAP micropillar diameter and interpillar spacing. 
 
macro "PillarAnalysis_10X [s]" { 
 
dir = getDirectory("Choose a Directory "); 




Roi_AverageFeret = newArray(list.length); 
Roi_StDevFeret = newArray(list.length); 
Roi_AverageInterpillar = newArray(list.length); 
Roi_StDevInterpillar = newArray(list.length); 
 




scale = 0.351; //um/pixel, 10XImage 
 












run("Convert to Mask"); 
//run("Dilate"); //Dilation included to match Keyence measurements 
run("Analyze Particles...", "size=30000-Infinity circularity=0.10-1.00 exclude add"); 
RoiN = roiManager("count"); 
 
Roi_X = newArray(RoiN); 
Roi_Y = newArray(RoiN); 
Roi_Feret = newArray(RoiN); 
Roi_Interpillar_Ave = newArray(RoiN); 
 
















//For each ROI: 
//Find nearest ROI and distance -- Output: Roi_Nearest[i], Roi_NearestDistance[i] 
for (i = 0; i < RoiN; i++) { 
 interpillar_count = 0; 
 interpillar_sum = 0; 
 
 for (j = 0; j < RoiN; j++) { 
  distance = sqrt((Roi_X[i]-Roi_X[j])*(Roi_X[i]-Roi_X[j])+(Roi_Y[i]-
Roi_Y[j])*(Roi_Y[i]-Roi_Y[j])); 
 
  if (distance != 0) { 
   if (distance < Roi_Feret[i]*1.75) { 
    interpillar = distance - Roi_Feret[i]/2 - Roi_Feret[j]/2; 
    interpillar_count = interpillar_count + 1; 
    interpillar_sum = interpillar_sum + interpillar; 
   } 
  } 
 } 
 Roi_Interpillar_Ave[i] = interpillar_sum/interpillar_count; 
} 
 
//print("Roi Feret Interpillar_Average"); 
print(list[k]); 
for (i=0; i<RoiN; i++){ 




Roi_AverageFeret[k] = 0; 
Roi_AverageInterpillar[k] = 0; 
for (i=0; i < RoiN; i++){ 
 Roi_AverageFeret[k] = Roi_AverageFeret[k] + Roi_Feret[i]; 




Roi_AverageFeret[k] = Roi_AverageFeret[k]/RoiN; 
Roi_AverageInterpillar[k] = Roi_AverageInterpillar[k]/RoiN; 
 
Roi_StDevFeret[k] = 0; 
Roi_StDevInterpillar[k] = 0; 
for (i=0; i < RoiN; i++){ 
 Roi_StDevFeret[k] = Roi_StDevFeret[k] + (Roi_Feret[i]-
Roi_AverageFeret[k])*(Roi_Feret[i]-Roi_AverageFeret[k]); 
 Roi_StDevInterpillar[k] = Roi_StDevInterpillar[k] + (Roi_Interpillar_Ave[i]-
Roi_AverageInterpillar[k])*(Roi_Interpillar_Ave[i]-Roi_AverageInterpillar[k]); 
} 
Roi_StDevFeret[k] = sqrt(Roi_StDevFeret[k]/(RoiN-1)); 






for (k=0; k < list.length; k++) { 











Table A2. Breast cancer patient demographic and diagnostic information. 
 
 
Table 6. Clinical information for breast cancer patient samples. Samples were obtained either from the Indian Creek 
clinic at KUMC or from the KUMC BRCF bank. N/A refers to no testing of the receptor. DCIS = ductal carcinoma in 
situ, ICD = invasive ductal carcinoma, IMC = invasive mammary carcinoma. Nodal involvement means cancer was 
found to metastasize into the lymph nodes through biopsy after neoadjuvant therapy. All samples collected in 2019 
came from the Indian Creek location of the University of Kansas Cancer Center, while the other samples were 
collected in 2017 and held in liquid nitrogen in the biorepository. 
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A3. Macro for measuring intensity in the EV-MAP microchannels produced from Cy-5 
labeled oligonucleotide  



















run("Convert to Mask"); 
run("Create Selection"); 
roiManager("Add"); 
 
roiManager("Select", 0); 
selectWindow(Name); 
roiManager("Measure"); 
 
selectWindow(NameDup); 
close (); 
} 
